Awad MM - Search Results

1

Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial.

Shu CA, Gainor JF, Awad MM, Chiuzan C, Grigg CM, Pabani A, Garofano RF, Stoopler MB, Cheng SK, White A, Lanuti M, D'Ovidio F, Bacchetta M, Sonett JR, Saqi A, Rizvi NA. Shu CA, et al. Among authors: awad mm. Lancet Oncol. 2020 Jun;21(6):786-795. doi: 10.1016/S1470-2045(20)30140-6. Epub 2020 May 7. Lancet Oncol. 2020. PMID: 32386568 Clinical Trial.

2

Pemetrexed-based chemotherapy in patients with advanced, ALK-positive non-small cell lung cancer.

Shaw AT, Varghese AM, Solomon BJ, Costa DB, Novello S, Mino-Kenudson M, Awad MM, Engelman JA, Riely GJ, Monica V, Yeap BY, Scagliotti GV. Shaw AT, et al. Among authors: awad mm. Ann Oncol. 2013 Jan;24(1):59-66. doi: 10.1093/annonc/mds242. Epub 2012 Aug 10. Ann Oncol. 2013. PMID: 22887466 Free PMC article.

3

Acquired resistance to crizotinib from a mutation in CD74-ROS1.

Awad MM, Katayama R, McTigue M, Liu W, Deng YL, Brooun A, Friboulet L, Huang D, Falk MD, Timofeevski S, Wilner KD, Lockerman EL, Khan TM, Mahmood S, Gainor JF, Digumarthy SR, Stone JR, Mino-Kenudson M, Christensen JG, Iafrate AJ, Engelman JA, Shaw AT. Awad MM, et al. N Engl J Med. 2013 Jun 20;368(25):2395-401. doi: 10.1056/NEJMoa1215530. Epub 2013 Jun 1. N Engl J Med. 2013. PMID: 23724914 Free PMC article.

4

ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer.

Gainor JF, Varghese AM, Ou SH, Kabraji S, Awad MM, Katayama R, Pawlak A, Mino-Kenudson M, Yeap BY, Riely GJ, Iafrate AJ, Arcila ME, Ladanyi M, Engelman JA, Dias-Santagata D, Shaw AT. Gainor JF, et al. Among authors: awad mm. Clin Cancer Res. 2013 Aug 1;19(15):4273-81. doi: 10.1158/1078-0432.CCR-13-0318. Epub 2013 May 31. Clin Cancer Res. 2013. PMID: 23729361 Free PMC article.

5

The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer.

Friboulet L, Li N, Katayama R, Lee CC, Gainor JF, Crystal AS, Michellys PY, Awad MM, Yanagitani N, Kim S, Pferdekamper AC, Li J, Kasibhatla S, Sun F, Sun X, Hua S, McNamara P, Mahmood S, Lockerman EL, Fujita N, Nishio M, Harris JL, Shaw AT, Engelman JA. Friboulet L, et al. Among authors: awad mm. Cancer Discov. 2014 Jun;4(6):662-673. doi: 10.1158/2159-8290.CD-13-0846. Epub 2014 Mar 27. Cancer Discov. 2014. PMID: 24675041 Free PMC article.

6

ALK inhibitors in non-small cell lung cancer: crizotinib and beyond.

Awad MM, Shaw AT. Awad MM, et al. Clin Adv Hematol Oncol. 2014 Jul;12(7):429-39. Clin Adv Hematol Oncol. 2014. PMID: 25322323 Free PMC article. Review.

7

Patient-derived models of acquired resistance can identify effective drug combinations for cancer.

Crystal AS, Shaw AT, Sequist LV, Friboulet L, Niederst MJ, Lockerman EL, Frias RL, Gainor JF, Amzallag A, Greninger P, Lee D, Kalsy A, Gomez-Caraballo M, Elamine L, Howe E, Hur W, Lifshits E, Robinson HE, Katayama R, Faber AC, Awad MM, Ramaswamy S, Mino-Kenudson M, Iafrate AJ, Benes CH, Engelman JA. Crystal AS, et al. Among authors: awad mm. Science. 2014 Dec 19;346(6216):1480-6. doi: 10.1126/science.1254721. Epub 2014 Nov 13. Science. 2014. PMID: 25394791 Free PMC article.

8

Successful desensitization of two patients with ALK-positive lung cancer and hypersensitivity to crizotinib.

Awad MM, Lax TP, Slawski BR, Shaw AT. Awad MM, et al. J Thorac Oncol. 2014 Nov;9(11):1726-8. doi: 10.1097/JTO.0000000000000350. J Thorac Oncol. 2014. PMID: 25436807 Free article.

9

Durable Responses With PD-1 Inhibition in Lung and Kidney Cancer and the Ongoing Search for Predictive Biomarkers.

Awad MM, Hammerman PS. Awad MM, et al. J Clin Oncol. 2015 Jun 20;33(18):1993-4. doi: 10.1200/JCO.2015.61.4172. Epub 2015 Apr 27. J Clin Oncol. 2015. PMID: 25918290 No abstract available.

10

Radiologic Heterogeneity in Responses to Anti-PD-1/PD-L1 Therapy in Metastatic Renal Cell Carcinoma.

de Velasco G, Krajewski KM, Albiges L, Awad MM, Bellmunt J, Hodi FS, Choueiri TK. de Velasco G, et al. Among authors: awad mm. Cancer Immunol Res. 2016 Jan;4(1):12-7. doi: 10.1158/2326-6066.CIR-15-0197. Epub 2015 Nov 20. Cancer Immunol Res. 2016. PMID: 26589768

11

Impaired c-Met Receptor Degradation Mediated by MET Exon 14 Mutations in Non-Small-Cell Lung Cancer.

Awad MM. Awad MM. J Clin Oncol. 2016 Mar 10;34(8):879-81. doi: 10.1200/JCO.2015.64.2777. Epub 2016 Jan 19. J Clin Oncol. 2016. PMID: 26786927 No abstract available.

12

Anti-PD-1 Inhibitor-Related Pneumonitis in Non-Small Cell Lung Cancer.

Nishino M, Chambers ES, Chong CR, Ramaiya NH, Gray SW, Marcoux JP, Hatabu H, Jänne PA, Hodi FS, Awad MM. Nishino M, et al. Among authors: awad mm. Cancer Immunol Res. 2016 Apr;4(4):289-93. doi: 10.1158/2326-6066.CIR-15-0267. Epub 2016 Feb 10. Cancer Immunol Res. 2016. PMID: 26865455 Free PMC article.

13

PD-1 Inhibitor-Related Pneumonitis in Advanced Cancer Patients: Radiographic Patterns and Clinical Course.

Nishino M, Ramaiya NH, Awad MM, Sholl LM, Maattala JA, Taibi M, Hatabu H, Ott PA, Armand PF, Hodi FS. Nishino M, et al. Among authors: awad mm. Clin Cancer Res. 2016 Dec 15;22(24):6051-6060. doi: 10.1158/1078-0432.CCR-16-1320. Epub 2016 Aug 17. Clin Cancer Res. 2016. PMID: 27535979 Free PMC article. Clinical Trial.

14

Multiparametric profiling of non-small-cell lung cancers reveals distinct immunophenotypes.

Lizotte PH, Ivanova EV, Awad MM, Jones RE, Keogh L, Liu H, Dries R, Almonte C, Herter-Sprie GS, Santos A, Feeney NB, Paweletz CP, Kulkarni MM, Bass AJ, Rustgi AK, Yuan GC, Kufe DW, Jänne PA, Hammerman PS, Sholl LM, Hodi FS, Richards WG, Bueno R, English JM, Bittinger MA, Wong KK. Lizotte PH, et al. Among authors: awad mm. JCI Insight. 2016 Sep 8;1(14):e89014. doi: 10.1172/jci.insight.89014. JCI Insight. 2016. PMID: 27699239 Free PMC article.

15

Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study.

Langer CJ, Gadgeel SM, Borghaei H, Papadimitrakopoulou VA, Patnaik A, Powell SF, Gentzler RD, Martins RG, Stevenson JP, Jalal SI, Panwalkar A, Yang JC, Gubens M, Sequist LV, Awad MM, Fiore J, Ge Y, Raftopoulos H, Gandhi L; KEYNOTE-021 investigators. Langer CJ, et al. Among authors: awad mm. Lancet Oncol. 2016 Nov;17(11):1497-1508. doi: 10.1016/S1470-2045(16)30498-3. Epub 2016 Oct 10. Lancet Oncol. 2016. PMID: 27745820 Free PMC article. Clinical Trial.

16

Estimating Survival in Patients With Lung Cancer and Brain Metastases: An Update of the Graded Prognostic Assessment for Lung Cancer Using Molecular Markers (Lung-molGPA).

Sperduto PW, Yang TJ, Beal K, Pan H, Brown PD, Bangdiwala A, Shanley R, Yeh N, Gaspar LE, Braunstein S, Sneed P, Boyle J, Kirkpatrick JP, Mak KS, Shih HA, Engelman A, Roberge D, Arvold ND, Alexander B, Awad MM, Contessa J, Chiang V, Hardie J, Ma D, Lou E, Sperduto W, Mehta MP. Sperduto PW, et al. Among authors: awad mm. JAMA Oncol. 2017 Jun 1;3(6):827-831. doi: 10.1001/jamaoncol.2016.3834. JAMA Oncol. 2017. PMID: 27892978 Free PMC article.

17

An open-label, phase II study of the polo-like kinase-1 (Plk-1) inhibitor, BI 2536, in patients with relapsed small cell lung cancer (SCLC).

Awad MM, Chu QS, Gandhi L, Stephenson JJ, Govindan R, Bradford DS, Bonomi PD, Ellison DM, Eaton KD, Fritsch H, Munzert G, Johnson BE, Socinski MA. Awad MM, et al. Lung Cancer. 2017 Feb;104:126-130. doi: 10.1016/j.lungcan.2016.12.019. Epub 2016 Dec 30. Lung Cancer. 2017. PMID: 28212994 Clinical Trial.

18

More valuable than platinum: first-line pembrolizumab in advanced stage non-small-cell lung cancer.

Zou T, Awad MM. Zou T, et al. Among authors: awad mm. Ann Oncol. 2017 Apr 1;28(4):685-687. doi: 10.1093/annonc/mdx083. Ann Oncol. 2017. PMID: 28327984 Free article. No abstract available.

19

Synergistic Immunostimulatory Effects and Therapeutic Benefit of Combined Histone Deacetylase and Bromodomain Inhibition in Non-Small Cell Lung Cancer.

Adeegbe DO, Liu Y, Lizotte PH, Kamihara Y, Aref AR, Almonte C, Dries R, Li Y, Liu S, Wang X, Warner-Hatten T, Castrillon J, Yuan GC, Poudel-Neupane N, Zhang H, Guerriero JL, Han S, Awad MM, Barbie DA, Ritz J, Jones SS, Hammerman PS, Bradner J, Quayle SN, Wong KK. Adeegbe DO, et al. Among authors: awad mm. Cancer Discov. 2017 Aug;7(8):852-867. doi: 10.1158/2159-8290.CD-16-1020. Epub 2017 Apr 13. Cancer Discov. 2017. PMID: 28408401 Free PMC article.

20

Diabetic Ketoacidosis as an Immune-related Adverse Event from Pembrolizumab in Non-Small Cell Lung Cancer.

Leonardi GC, Oxnard GR, Haas A, Lang JP, Williams JS, Awad MM. Leonardi GC, et al. Among authors: awad mm. J Immunother. 2017 Jul/Aug;40(6):249-251. doi: 10.1097/CJI.0000000000000173. J Immunother. 2017. PMID: 28557813

21

Radiation and PD-1 inhibition: Favorable outcomes after brain-directed radiation.

Pike LRG, Bang A, Ott P, Balboni T, Taylor A, Catalano P, Rawal B, Spektor A, Krishnan M, Cagney D, Alexander B, Aizer AA, Buchbinder E, Awad M, Gandhi L, Hodi FS, Schoenfeld JD. Pike LRG, et al. Radiother Oncol. 2017 Jul;124(1):98-103. doi: 10.1016/j.radonc.2017.06.006. Epub 2017 Jun 26. Radiother Oncol. 2017. PMID: 28662869

22

Tumor Response Dynamics of Advanced Non-small Cell Lung Cancer Patients Treated with PD-1 Inhibitors: Imaging Markers for Treatment Outcome.

Nishino M, Dahlberg SE, Adeni AE, Lydon CA, Hatabu H, Jänne PA, Hodi FS, Awad MM. Nishino M, et al. Among authors: awad mm. Clin Cancer Res. 2017 Oct 1;23(19):5737-5744. doi: 10.1158/1078-0432.CCR-17-1434. Epub 2017 Jul 5. Clin Cancer Res. 2017. PMID: 28679767 Free PMC article.

23

Safety and Efficacy of PD-1 Inhibitors Among HIV-Positive Patients With Non-Small Cell Lung Cancer.

Ostios-Garcia L, Faig J, Leonardi GC, Adeni AE, Subegdjo SJ, Lydon CA, Rangachari D, Huberman MS, Sehgal K, Shea M, VanderLaan PA, Cheng MP, Marty FM, Hammond SP, Costa DB, Awad MM. Ostios-Garcia L, et al. Among authors: awad mm. J Thorac Oncol. 2018 Jul;13(7):1037-1042. doi: 10.1016/j.jtho.2018.03.031. Epub 2018 Apr 6. J Thorac Oncol. 2018. PMID: 29631035 Free article.

24

Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer.

Gandhi L, Rodríguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, Domine M, Clingan P, Hochmair MJ, Powell SF, Cheng SY, Bischoff HG, Peled N, Grossi F, Jennens RR, Reck M, Hui R, Garon EB, Boyer M, Rubio-Viqueira B, Novello S, Kurata T, Gray JE, Vida J, Wei Z, Yang J, Raftopoulos H, Pietanza MC, Garassino MC; KEYNOTE-189 Investigators. Gandhi L, et al. N Engl J Med. 2018 May 31;378(22):2078-2092. doi: 10.1056/NEJMoa1801005. Epub 2018 Apr 16. N Engl J Med. 2018. PMID: 29658856 Free article. Clinical Trial.

25

Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer.

Hellmann MD, Callahan MK, Awad MM, Calvo E, Ascierto PA, Atmaca A, Rizvi NA, Hirsch FR, Selvaggi G, Szustakowski JD, Sasson A, Golhar R, Vitazka P, Chang H, Geese WJ, Antonia SJ. Hellmann MD, et al. Among authors: awad mm. Cancer Cell. 2018 May 14;33(5):853-861.e4. doi: 10.1016/j.ccell.2018.04.001. Epub 2018 May 3. Cancer Cell. 2018. PMID: 29731394 Free PMC article.

26

Safety of Programmed Death-1 Pathway Inhibitors Among Patients With Non-Small-Cell Lung Cancer and Preexisting Autoimmune Disorders.

Leonardi GC, Gainor JF, Altan M, Kravets S, Dahlberg SE, Gedmintas L, Azimi R, Rizvi H, Riess JW, Hellmann MD, Awad MM. Leonardi GC, et al. Among authors: awad mm. J Clin Oncol. 2018 Jul 1;36(19):1905-1912. doi: 10.1200/JCO.2017.77.0305. Epub 2018 May 10. J Clin Oncol. 2018. PMID: 29746230 Free PMC article.

27

STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma.

Skoulidis F, Goldberg ME, Greenawalt DM, Hellmann MD, Awad MM, Gainor JF, Schrock AB, Hartmaier RJ, Trabucco SE, Gay L, Ali SM, Elvin JA, Singal G, Ross JS, Fabrizio D, Szabo PM, Chang H, Sasson A, Srinivasan S, Kirov S, Szustakowski J, Vitazka P, Edwards R, Bufill JA, Sharma N, Ou SI, Peled N, Spigel DR, Rizvi H, Aguilar EJ, Carter BW, Erasmus J, Halpenny DF, Plodkowski AJ, Long NM, Nishino M, Denning WL, Galan-Cobo A, Hamdi H, Hirz T, Tong P, Wang J, Rodriguez-Canales J, Villalobos PA, Parra ER, Kalhor N, Sholl LM, Sauter JL, Jungbluth AA, Mino-Kenudson M, Azimi R, Elamin YY, Zhang J, Leonardi GC, Jiang F, Wong KK, Lee JJ, Papadimitrakopoulou VA, Wistuba II, Miller VA, Frampton GM, Wolchok JD, Shaw AT, Jänne PA, Stephens PJ, Rudin CM, Geese WJ, Albacker LA, Heymach JV. Skoulidis F, et al. Among authors: awad mm. Cancer Discov. 2018 Jul;8(7):822-835. doi: 10.1158/2159-8290.CD-18-0099. Epub 2018 May 17. Cancer Discov. 2018. PMID: 29773717 Free PMC article. Clinical Trial.

28

Frequency of Brain Metastases and Multikinase Inhibitor Outcomes in Patients With RET-Rearranged Lung Cancers.

Drilon A, Lin JJ, Filleron T, Ni A, Milia J, Bergagnini I, Hatzoglou V, Velcheti V, Offin M, Li B, Carbone DP, Besse B, Mok T, Awad MM, Wolf J, Owen D, Camidge DR, Riely GJ, Peled N, Kris MG, Mazieres J, Gainor JF, Gautschi O. Drilon A, et al. Among authors: awad mm. J Thorac Oncol. 2018 Oct;13(10):1595-1601. doi: 10.1016/j.jtho.2018.07.004. Epub 2018 Jul 11. J Thorac Oncol. 2018. PMID: 30017832 Free PMC article.

29

24-Month Overall Survival from KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin with or without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous Non-Small Cell Lung Cancer.

Borghaei H, Langer CJ, Gadgeel S, Papadimitrakopoulou VA, Patnaik A, Powell SF, Gentzler RD, Martins RG, Stevenson JP, Jalal SI, Panwalkar A, Yang JC, Gubens M, Sequist LV, Awad MM, Fiore J, Saraf S, Keller SM, Gandhi L. Borghaei H, et al. Among authors: awad mm. J Thorac Oncol. 2019 Jan;14(1):124-129. doi: 10.1016/j.jtho.2018.08.004. Epub 2018 Aug 21. J Thorac Oncol. 2019. PMID: 30138764 Free article.

30

PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers.

Sabari JK, Leonardi GC, Shu CA, Umeton R, Montecalvo J, Ni A, Chen R, Dienstag J, Mrad C, Bergagnini I, Lai WV, Offin M, Arbour KC, Plodkowski AJ, Halpenny DF, Paik PK, Li BT, Riely GJ, Kris MG, Rudin CM, Sholl LM, Nishino M, Hellmann MD, Rekhtman N, Awad MM, Drilon A. Sabari JK, et al. Among authors: awad mm. Ann Oncol. 2018 Oct 1;29(10):2085-2091. doi: 10.1093/annonc/mdy334. Ann Oncol. 2018. PMID: 30165371 Free PMC article.

31

First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers.

Ready N, Hellmann MD, Awad MM, Otterson GA, Gutierrez M, Gainor JF, Borghaei H, Jolivet J, Horn L, Mates M, Brahmer J, Rabinowitz I, Reddy PS, Chesney J, Orcutt J, Spigel DR, Reck M, O'Byrne KJ, Paz-Ares L, Hu W, Zerba K, Li X, Lestini B, Geese WJ, Szustakowski JD, Green G, Chang H, Ramalingam SS. Ready N, et al. Among authors: awad mm. J Clin Oncol. 2019 Apr 20;37(12):992-1000. doi: 10.1200/JCO.18.01042. Epub 2019 Feb 20. J Clin Oncol. 2019. PMID: 30785829 Free PMC article. Clinical Trial.

32

Frequency and imaging features of abdominal immune-related adverse events in metastatic lung cancer patients treated with PD-1 inhibitor.

Alessandrino F, Sahu S, Nishino M, Adeni AE, Tirumani SH, Shinagare AB, Awad MM. Alessandrino F, et al. Among authors: awad mm. Abdom Radiol (NY). 2019 May;44(5):1917-1927. doi: 10.1007/s00261-019-01935-2. Abdom Radiol (NY). 2019. PMID: 30790009

33

Use of targeted next generation sequencing to characterize tumor mutational burden and efficacy of immune checkpoint inhibition in small cell lung cancer.

Ricciuti B, Kravets S, Dahlberg SE, Umeton R, Albayrak A, Subegdjo SJ, Johnson BE, Nishino M, Sholl LM, Awad MM. Ricciuti B, et al. Among authors: awad mm. J Immunother Cancer. 2019 Mar 28;7(1):87. doi: 10.1186/s40425-019-0572-6. J Immunother Cancer. 2019. PMID: 30922388 Free PMC article.

34

Tumor Volume Analysis as a Predictive Marker for Prolonged Survival in Anaplastic Lymphoma Kinase-rearranged Advanced Non-Small Cell Lung Cancer Patients Treated With Crizotinib.

Hida T, Dahlberg SE, Lydon CA, Hatabu H, Johnson BE, Awad MM, Nishino M. Hida T, et al. Among authors: awad mm. J Thorac Imaging. 2020 Mar;35(2):101-107. doi: 10.1097/RTI.0000000000000413. J Thorac Imaging. 2020. PMID: 30985604

35

EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer.

Hastings K, Yu HA, Wei W, Sanchez-Vega F, DeVeaux M, Choi J, Rizvi H, Lisberg A, Truini A, Lydon CA, Liu Z, Henick BS, Wurtz A, Cai G, Plodkowski AJ, Long NM, Halpenny DF, Killam J, Oliva I, Schultz N, Riely GJ, Arcila ME, Ladanyi M, Zelterman D, Herbst RS, Goldberg SB, Awad MM, Garon EB, Gettinger S, Hellmann MD, Politi K. Hastings K, et al. Among authors: awad mm. Ann Oncol. 2019 Aug 1;30(8):1311-1320. doi: 10.1093/annonc/mdz141. Ann Oncol. 2019. PMID: 31086949 Free PMC article.

36

Impact of MET inhibitors on survival among patients with non-small cell lung cancer harboring MET exon 14 mutations: a retrospective analysis.

Awad MM, Leonardi GC, Kravets S, Dahlberg SE, Drilon A, Noonan SA, Camidge DR, Ou SI, Costa DB, Gadgeel SM, Steuer CE, Forde PM, Zhu VW, Fukuda Y, Clark JW, Jänne PA, Mok T, Sholl LM, Heist RS. Awad MM, et al. Lung Cancer. 2019 Jul;133:96-102. doi: 10.1016/j.lungcan.2019.05.011. Epub 2019 May 11. Lung Cancer. 2019. PMID: 31200835 Free PMC article.

37

Immune Checkpoint Inhibitor Outcomes for Patients With Non-Small-Cell Lung Cancer Receiving Baseline Corticosteroids for Palliative Versus Nonpalliative Indications.

Ricciuti B, Dahlberg SE, Adeni A, Sholl LM, Nishino M, Awad MM. Ricciuti B, et al. Among authors: awad mm. J Clin Oncol. 2019 Aug 1;37(22):1927-1934. doi: 10.1200/JCO.19.00189. Epub 2019 Jun 17. J Clin Oncol. 2019. PMID: 31206316

38

Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression.

Aguilar EJ, Ricciuti B, Gainor JF, Kehl KL, Kravets S, Dahlberg S, Nishino M, Sholl LM, Adeni A, Subegdjo S, Khosrowjerdi S, Peterson RM, Digumarthy S, Liu C, Sauter J, Rizvi H, Arbour KC, Carter BW, Heymach JV, Altan M, Hellmann MD, Awad MM. Aguilar EJ, et al. Among authors: awad mm. Ann Oncol. 2019 Oct 1;30(10):1653-1659. doi: 10.1093/annonc/mdz288. Ann Oncol. 2019. PMID: 31435660 Free article.

39

Immune Checkpoint Inhibitor Therapy in Patients With Preexisting Inflammatory Bowel Disease.

Abu-Sbeih H, Faleck DM, Ricciuti B, Mendelsohn RB, Naqash AR, Cohen JV, Sellers MC, Balaji A, Ben-Betzalel G, Hajir I, Zhang J, Awad MM, Leonardi GC, Johnson DB, Pinato DJ, Owen DH, Weiss SA, Lamberti G, Lythgoe MP, Manuzzi L, Arnold C, Qiao W, Naidoo J, Markel G, Powell N, Yeung SJ, Sharon E, Dougan M, Wang Y. Abu-Sbeih H, et al. Among authors: awad mm. J Clin Oncol. 2020 Feb 20;38(6):576-583. doi: 10.1200/JCO.19.01674. Epub 2019 Dec 4. J Clin Oncol. 2020. PMID: 31800340 Free PMC article.

40

Clinical activity of programmed cell death 1 (PD-1) blockade in never, light, and heavy smokers with non-small-cell lung cancer and PD-L1 expression ≥50.

Gainor JF, Rizvi H, Jimenez Aguilar E, Skoulidis F, Yeap BY, Naidoo J, Khosrowjerdi S, Mooradian M, Lydon C, Illei P, Zhang J, Peterson R, Ricciuti B, Nishino M, Zhang J, Roth JA, Grishman J, Anderson D, Little BP, Carter BW, Arbour K, Sauter JL, Mino-Kenudson M, Heymach JV, Digumarthy S, Shaw AT, Awad MM, Hellmann MD. Gainor JF, et al. Among authors: awad mm. Ann Oncol. 2020 Mar;31(3):404-411. doi: 10.1016/j.annonc.2019.11.015. Epub 2019 Dec 9. Ann Oncol. 2020. PMID: 32067682 Free PMC article.

41

Phase 1 study of epacadostat in combination with atezolizumab for patients with previously treated advanced nonsmall cell lung cancer.

Hellmann MD, Gettinger S, Chow LQM, Gordon M, Awad MM, Cha E, Gong X, Zhou G, Walker C, Leopold L, Heist RS. Hellmann MD, et al. Among authors: awad mm. Int J Cancer. 2020 Oct 1;147(7):1963-1969. doi: 10.1002/ijc.32951. Epub 2020 Mar 20. Int J Cancer. 2020. PMID: 32141617 Free PMC article. Clinical Trial.

42

Clinicopathological and genomic correlates of programmed cell death ligand 1 (PD-L1) expression in nonsquamous non-small-cell lung cancer.

Lamberti G, Spurr LF, Li Y, Ricciuti B, Recondo G, Umeton R, Nishino M, Sholl LM, Meyerson ML, Cherniack AD, Awad MM. Lamberti G, et al. Among authors: awad mm. Ann Oncol. 2020 Jun;31(6):807-814. doi: 10.1016/j.annonc.2020.02.017. Epub 2020 Apr 27. Ann Oncol. 2020. PMID: 32171752 Free article.

43

Immunotherapy in lung cancer: effective for patients with poor performance status?

Alessi JV, Awad MM. Alessi JV, et al. Among authors: awad mm. Lancet Respir Med. 2020 Sep;8(9):838-839. doi: 10.1016/S2213-2600(20)30107-7. Epub 2020 Mar 19. Lancet Respir Med. 2020. PMID: 32199467 No abstract available.

44

Impact of DNA Damage Response and Repair (DDR) Gene Mutations on Efficacy of PD-(L)1 Immune Checkpoint Inhibition in Non-Small Cell Lung Cancer.

Ricciuti B, Recondo G, Spurr LF, Li YY, Lamberti G, Venkatraman D, Umeton R, Cherniack AD, Nishino M, Sholl LM, Shapiro GI, Awad MM, Cheng ML. Ricciuti B, et al. Among authors: awad mm. Clin Cancer Res. 2020 Aug 1;26(15):4135-4142. doi: 10.1158/1078-0432.CCR-19-3529. Epub 2020 Apr 24. Clin Cancer Res. 2020. PMID: 32332016

45

Safety and efficacy of immune checkpoint inhibitors in patients with non-small cell lung cancer and hepatitis B or hepatitis C infection.

Pertejo-Fernandez A, Ricciuti B, Hammond SP, Marty FM, Recondo G, Rangachari D, Costa DB, Awad MM. Pertejo-Fernandez A, et al. Among authors: awad mm. Lung Cancer. 2020 Jul;145:181-185. doi: 10.1016/j.lungcan.2020.02.013. Epub 2020 Feb 24. Lung Cancer. 2020. PMID: 32423643

46

Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study.

Rudin CM, Awad MM, Navarro A, Gottfried M, Peters S, Csőszi T, Cheema PK, Rodriguez-Abreu D, Wollner M, Yang JC, Mazieres J, Orlandi FJ, Luft A, Gümüş M, Kato T, Kalemkerian GP, Luo Y, Ebiana V, Pietanza MC, Kim HR; KEYNOTE-604 Investigators. Rudin CM, et al. Among authors: awad mm. J Clin Oncol. 2020 Jul 20;38(21):2369-2379. doi: 10.1200/JCO.20.00793. Epub 2020 May 29. J Clin Oncol. 2020. PMID: 32468956 Free PMC article. Clinical Trial.

47

Park H, Hatabu H, Ricciuti B, Aijazi SJ, Awad MM, Nishino M. Park H, et al. Among authors: awad mm. Eur J Radiol. 2020 Nov;132:109275. doi: 10.1016/j.ejrad.2020.109275. Epub 2020 Sep 10. Eur J Radiol. 2020. PMID: 32949913 Free PMC article.

48

Plasma IL-6 changes correlate to PD-1 inhibitor responses in NSCLC.

Keegan A, Ricciuti B, Garden P, Cohen L, Nishihara R, Adeni A, Paweletz C, Supplee J, Jänne PA, Severgnini M, Awad MM, Walt DR. Keegan A, et al. Among authors: awad mm. J Immunother Cancer. 2020 Oct;8(2):e000678. doi: 10.1136/jitc-2020-000678. J Immunother Cancer. 2020. PMID: 33020238 Free PMC article.

49

A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer.

Ott PA, Hu-Lieskovan S, Chmielowski B, Govindan R, Naing A, Bhardwaj N, Margolin K, Awad MM, Hellmann MD, Lin JJ, Friedlander T, Bushway ME, Balogh KN, Sciuto TE, Kohler V, Turnbull SJ, Besada R, Curran RR, Trapp B, Scherer J, Poran A, Harjanto D, Barthelme D, Ting YS, Dong JZ, Ware Y, Huang Y, Huang Z, Wanamaker A, Cleary LD, Moles MA, Manson K, Greshock J, Khondker ZS, Fritsch E, Rooney MS, DeMario M, Gaynor RB, Srinivasan L. Ott PA, et al. Among authors: awad mm. Cell. 2020 Oct 15;183(2):347-362.e24. doi: 10.1016/j.cell.2020.08.053. Cell. 2020. PMID: 33064988 Free article. Clinical Trial.

50

Long-Term Overall Survival From KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin With or Without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous NSCLC.

Awad MM, Gadgeel SM, Borghaei H, Patnaik A, Yang JC, Powell SF, Gentzler RD, Martins RG, Stevenson JP, Altan M, Jalal SI, Panwalkar A, Gubens M, Sequist LV, Saraf S, Zhao B, Piperdi B, Langer CJ. Awad MM, et al. J Thorac Oncol. 2021 Jan;16(1):162-168. doi: 10.1016/j.jtho.2020.09.015. Epub 2020 Oct 15. J Thorac Oncol. 2021. PMID: 33069888 Free article. Clinical Trial.

51

What Is the Standard First-Line Treatment for Advanced Non-Small Cell Lung Cancer?

Ricciuti B, Awad MM. Ricciuti B, et al. Among authors: awad mm. Cancer J. 2020 Nov/Dec;26(6):485-495. doi: 10.1097/PPO.0000000000000489. Cancer J. 2020. PMID: 33298719 Review.

52

Association between Smoking History and Tumor Mutation Burden in Advanced Non-Small Cell Lung Cancer.

Wang X, Ricciuti B, Nguyen T, Li X, Rabin MS, Awad MM, Lin X, Johnson BE, Christiani DC. Wang X, et al. Among authors: awad mm. Cancer Res. 2021 May 1;81(9):2566-2573. doi: 10.1158/0008-5472.CAN-20-3991. Epub 2021 Mar 2. Cancer Res. 2021. PMID: 33653773 Free PMC article.

53

Exclusion of patients living with HIV from cancer immune checkpoint inhibitor trials.

Vora KB, Ricciuti B, Awad MM. Vora KB, et al. Among authors: awad mm. Sci Rep. 2021 Mar 23;11(1):6637. doi: 10.1038/s41598-021-86081-w. Sci Rep. 2021. PMID: 33758321 Free PMC article.

54

Tumor Response Dynamics During First-Line Pembrolizumab Therapy in Patients With Advanced Non-Small-Cell Lung Cancer.

Nishino M, Hong F, Ricciuti B, Hatabu H, Awad MM. Nishino M, et al. Among authors: awad mm. JCO Precis Oncol. 2021 Mar 19;5:PO.20.00478. doi: 10.1200/PO.20.00478. eCollection 2021. JCO Precis Oncol. 2021. PMID: 34250409 Free PMC article.

55

Antibiotic-exposed patients with non-small-cell lung cancer preserve efficacy outcomes following first-line chemo-immunotherapy.

Cortellini A, Ricciuti B, Facchinetti F, Alessi JVM, Venkatraman D, Dall'Olio FG, Cravero P, Vaz VR, Ottaviani D, Majem M, Piedra A, Sullivan I, Lee KA, Lamberti G, Hussain N, Clark J, Bolina A, Barba A, Benitez JC, Gorría T, Mezquita L, Hoton D, Aboubakar Nana F, Besse B, Awad MM, Pinato DJ. Cortellini A, et al. Among authors: awad mm. Ann Oncol. 2021 Nov;32(11):1391-1399. doi: 10.1016/j.annonc.2021.08.1744. Epub 2021 Aug 13. Ann Oncol. 2021. PMID: 34400292 Free article.

56

Characterization of Non-Small-Cell Lung Cancers With MET Exon 14 Skipping Alterations Detected in Tissue or Liquid: Clinicogenomics and Real-World Treatment Patterns.

Lee JK, Madison R, Classon A, Gjoerup O, Rosenzweig M, Frampton GM, Alexander BM, Oxnard GR, Venstrom JM, Awad MM, Schrock AB. Lee JK, et al. Among authors: awad mm. JCO Precis Oncol. 2021 Aug 25;5:PO.21.00122. doi: 10.1200/PO.21.00122. eCollection 2021. JCO Precis Oncol. 2021. PMID: 34476332 Free PMC article.

57

JASPER: Phase 2 trial of first-line niraparib plus pembrolizumab in patients with advanced non-small cell lung cancer.

Ramalingam SS, Thara E, Awad MM, Dowlati A, Haque B, Stinchcombe TE, Dy GK, Spigel DR, Lu S, Iyer Singh N, Tang Y, Teslenko I, Iannotti N. Ramalingam SS, et al. Among authors: awad mm. Cancer. 2022 Jan 1;128(1):65-74. doi: 10.1002/cncr.33885. Epub 2021 Sep 3. Cancer. 2022. PMID: 34478166 Free PMC article. Clinical Trial.

58

Clinical definition of acquired resistance to immunotherapy in patients with metastatic non-small-cell lung cancer.

Schoenfeld AJ, Antonia SJ, Awad MM, Felip E, Gainor J, Gettinger SN, Hodi FS, Johnson ML, Leighl NB, Lovly CM, Mok T, Perol M, Reck M, Solomon B, Soria JC, Tan DSW, Peters S, Hellmann MD. Schoenfeld AJ, et al. Among authors: awad mm. Ann Oncol. 2021 Dec;32(12):1597-1607. doi: 10.1016/j.annonc.2021.08.2151. Epub 2021 Sep 3. Ann Oncol. 2021. PMID: 34487855 Free article.

59

Selective Histone Deacetylase Inhibitor ACY-241 (Citarinostat) Plus Nivolumab in Advanced Non-Small Cell Lung Cancer: Results From a Phase Ib Study.

Awad MM, Le Bruchec Y, Lu B, Ye J, Miller J, Lizotte PH, Cavanaugh ME, Rode AJ, Dumitru CD, Spira A. Awad MM, et al. Front Oncol. 2021 Sep 6;11:696512. doi: 10.3389/fonc.2021.696512. eCollection 2021. Front Oncol. 2021. PMID: 34552864 Free PMC article.

60

Association Between Immune-Related Adverse Events and Clinical Outcomes to Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Blockade in SCLC.

Ricciuti B, Naqash AR, Naidoo J, Sehgal K, Miller A, Kehl K, Venkatraman D, Sands J, Lamberti G, Recondo G, Zhang J, Macherla S, Baig S, Walker P, Rangachari D, Gainor JF, Costa DB, Rizvi N, Sholl LM, Nishino M, Henick B, Farago AF, Awad MM. Ricciuti B, et al. Among authors: awad mm. JTO Clin Res Rep. 2020 Jul 15;1(4):100074. doi: 10.1016/j.jtocrr.2020.100074. eCollection 2020 Nov. JTO Clin Res Rep. 2020. PMID: 34589955 Free PMC article.

61

Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status.

Ricciuti B, Arbour KC, Lin JJ, Vajdi A, Vokes N, Hong L, Zhang J, Tolstorukov MY, Li YY, Spurr LF, Cherniack AD, Recondo G, Lamberti G, Wang X, Venkatraman D, Alessi JV, Vaz VR, Rizvi H, Egger J, Plodkowski AJ, Khosrowjerdi S, Digumarthy S, Park H, Vaz N, Nishino M, Sholl LM, Barbie D, Altan M, Heymach JV, Skoulidis F, Gainor JF, Hellmann MD, Awad MM. Ricciuti B, et al. Among authors: awad mm. J Thorac Oncol. 2022 Mar;17(3):399-410. doi: 10.1016/j.jtho.2021.10.013. Epub 2021 Nov 2. J Thorac Oncol. 2022. PMID: 34740862 Free PMC article.

62

Low peripheral blood derived neutrophil-to-lymphocyte ratio (dNLR) is associated with increased tumor T-cell infiltration and favorable outcomes to first-line pembrolizumab in non-small cell lung cancer.

Alessi JV, Ricciuti B, Alden SL, Bertram AA, Lin JJ, Sakhi M, Nishino M, Vaz VR, Lindsay J, Turner MM, Pfaff K, Sharma B, Felt KD, Rodig SJ, Gainor JF, Awad MM. Alessi JV, et al. Among authors: awad mm. J Immunother Cancer. 2021 Nov;9(11):e003536. doi: 10.1136/jitc-2021-003536. J Immunother Cancer. 2021. PMID: 34824161 Free PMC article.

63

Plasma cfDNA Genotyping in Hospitalized Patients With Suspected Metastatic NSCLC.

Cheng ML, Milan MSD, Tamen RM, Bertram AA, Michael KS, Ricciuti B, Kehl KL, Awad MM, Sholl LM, Paweletz CP, Jänne PA. Cheng ML, et al. Among authors: awad mm. JCO Precis Oncol. 2021 Nov;5:726-732. doi: 10.1200/PO.21.00029. JCO Precis Oncol. 2021. PMID: 34994618

64

Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial.

Schoenfeld JD, Giobbie-Hurder A, Ranasinghe S, Kao KZ, Lako A, Tsuji J, Liu Y, Brennick RC, Gentzler RD, Lee C, Hubbard J, Arnold SM, Abbruzzese JL, Jabbour SK, Uboha NV, Stephans KL, Johnson JM, Park H, Villaruz LC, Sharon E, Streicher H, Ahmed MM, Lyon H, Cibuskis C, Lennon N, Jhaveri A, Yang L, Altreuter J, Gunasti L, Weirather JL, Mak RH, Awad MM, Rodig SJ, Chen HX, Wu CJ, Monjazeb AM, Hodi FS. Schoenfeld JD, et al. Among authors: awad mm. Lancet Oncol. 2022 Feb;23(2):279-291. doi: 10.1016/S1470-2045(21)00658-6. Epub 2022 Jan 13. Lancet Oncol. 2022. PMID: 35033226 Free PMC article. Clinical Trial.

65

Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer.

Forde PM, Spicer J, Lu S, Provencio M, Mitsudomi T, Awad MM, Felip E, Broderick SR, Brahmer JR, Swanson SJ, Kerr K, Wang C, Ciuleanu TE, Saylors GB, Tanaka F, Ito H, Chen KN, Liberman M, Vokes EE, Taube JM, Dorange C, Cai J, Fiore J, Jarkowski A, Balli D, Sausen M, Pandya D, Calvet CY, Girard N; CheckMate 816 Investigators. Forde PM, et al. Among authors: awad mm. N Engl J Med. 2022 May 26;386(21):1973-1985. doi: 10.1056/NEJMoa2202170. Epub 2022 Apr 11. N Engl J Med. 2022. PMID: 35403841 Free PMC article. Clinical Trial.

66

Retrospective Review of Outcomes After Radiation Therapy for Oligoprogressive Disease on Immune Checkpoint Blockade.

Mahmood U, Huynh MA, Killoran JH, Qian JM, Bent EH, Aizer AA, Mak RH, Mamon HJ, Balboni TA, Gunasti L, Ott PA, Awad MM, Schoenfeld JD. Mahmood U, et al. Among authors: awad mm. Int J Radiat Oncol Biol Phys. 2022 Nov 15;114(4):666-675. doi: 10.1016/j.ijrobp.2022.05.008. Epub 2022 May 26. Int J Radiat Oncol Biol Phys. 2022. PMID: 35643252

67

Association of High Tumor Mutation Burden in Non-Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression Levels.

Ricciuti B, Wang X, Alessi JV, Rizvi H, Mahadevan NR, Li YY, Polio A, Lindsay J, Umeton R, Sinha R, Vokes NI, Recondo G, Lamberti G, Lawrence M, Vaz VR, Leonardi GC, Plodkowski AJ, Gupta H, Cherniack AD, Tolstorukov MY, Sharma B, Felt KD, Gainor JF, Ravi A, Getz G, Schalper KA, Henick B, Forde P, Anagnostou V, Jänne PA, Van Allen EM, Nishino M, Sholl LM, Christiani DC, Lin X, Rodig SJ, Hellmann MD, Awad MM. Ricciuti B, et al. Among authors: awad mm. JAMA Oncol. 2022 Aug 1;8(8):1160-1168. doi: 10.1001/jamaoncol.2022.1981. JAMA Oncol. 2022. PMID: 35708671 Free PMC article.

68

Dissecting the clinicopathologic, genomic, and immunophenotypic correlates of KRAS^G12D-mutated non-small-cell lung cancer.

Ricciuti B, Alessi JV, Elkrief A, Wang X, Cortellini A, Li YY, Vaz VR, Gupta H, Pecci F, Barrichello A, Lamberti G, Nguyen T, Lindsay J, Sharma B, Felt K, Rodig SJ, Nishino M, Sholl LM, Barbie DA, Negrao MV, Zhang J, Cherniack AD, Heymach JV, Meyerson M, Ambrogio C, Jänne PA, Arbour KC, Pinato DJ, Skoulidis F, Schoenfeld AJ, Awad MM, Luo J. Ricciuti B, et al. Among authors: awad mm. Ann Oncol. 2022 Oct;33(10):1029-1040. doi: 10.1016/j.annonc.2022.07.005. Epub 2022 Jul 22. Ann Oncol. 2022. PMID: 35872166 Free PMC article.

69

Personalized neoantigen vaccine NEO-PV-01 with chemotherapy and anti-PD-1 as first-line treatment for non-squamous non-small cell lung cancer.

Awad MM, Govindan R, Balogh KN, Spigel DR, Garon EB, Bushway ME, Poran A, Sheen JH, Kohler V, Esaulova E, Srouji J, Ramesh S, Vyasamneni R, Karki B, Sciuto TE, Sethi H, Dong JZ, Moles MA, Manson K, Rooney MS, Khondker ZS, DeMario M, Gaynor RB, Srinivasan L. Awad MM, et al. Cancer Cell. 2022 Sep 12;40(9):1010-1026.e11. doi: 10.1016/j.ccell.2022.08.003. Epub 2022 Aug 25. Cancer Cell. 2022. PMID: 36027916 Free article. Clinical Trial.

70

Molecular Characterization and Therapeutic Approaches to Small Cell Lung Cancer: Imaging Implications.

Park H, Tseng SC, Sholl LM, Hatabu H, Awad MM, Nishino M. Park H, et al. Among authors: awad mm. Radiology. 2022 Dec;305(3):512-525. doi: 10.1148/radiol.220585. Epub 2022 Oct 25. Radiology. 2022. PMID: 36283111 Free PMC article. Review.

71

Tumor Volume Nadir in Patients With ALK-Rearranged Non-Small-Cell Lung Cancer Treated With Alectinib.

Nishino M, Wei Z, Mazzola E, Hino T, Tseng SC, Sanchez ME, Hatabu H, Johnson BE, Awad MM. Nishino M, et al. Among authors: awad mm. JCO Precis Oncol. 2023 Mar;7:e2200603. doi: 10.1200/PO.22.00603. JCO Precis Oncol. 2023. PMID: 36893377

72

Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer.

Ravi A, Hellmann MD, Arniella MB, Holton M, Freeman SS, Naranbhai V, Stewart C, Leshchiner I, Kim J, Akiyama Y, Griffin AT, Vokes NI, Sakhi M, Kamesan V, Rizvi H, Ricciuti B, Forde PM, Anagnostou V, Riess JW, Gibbons DL, Pennell NA, Velcheti V, Digumarthy SR, Mino-Kenudson M, Califano A, Heymach JV, Herbst RS, Brahmer JR, Schalper KA, Velculescu VE, Henick BS, Rizvi N, Jänne PA, Awad MM, Chow A, Greenbaum BD, Luksza M, Shaw AT, Wolchok J, Hacohen N, Getz G, Gainor JF. Ravi A, et al. Among authors: awad mm. Nat Genet. 2023 May;55(5):807-819. doi: 10.1038/s41588-023-01355-5. Epub 2023 Apr 6. Nat Genet. 2023. PMID: 37024582 Free PMC article.

73

Dabrafenib in combination with trametinib for the treatment of metastatic melanoma.

Awad MM, Sullivan RJ. Awad MM, et al. Expert Rev Clin Pharmacol. 2015 Jan;8(1):25-33. doi: 10.1586/17512433.2015.974556. Epub 2014 Dec 4. Expert Rev Clin Pharmacol. 2015. PMID: 25473943 Review.

74

MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression.

Awad MM, Oxnard GR, Jackman DM, Savukoski DO, Hall D, Shivdasani P, Heng JC, Dahlberg SE, Jänne PA, Verma S, Christensen J, Hammerman PS, Sholl LM. Awad MM, et al. J Clin Oncol. 2016 Mar 1;34(7):721-30. doi: 10.1200/JCO.2015.63.4600. Epub 2016 Jan 4. J Clin Oncol. 2016. PMID: 26729443

75

The Effect of Gene Alterations and Tyrosine Kinase Inhibition on Survival and Cause of Death in Patients With Adenocarcinoma of the Lung and Brain Metastases.

Sperduto PW, Yang TJ, Beal K, Pan H, Brown PD, Bangdiwala A, Shanley R, Yeh N, Gaspar LE, Braunstein S, Sneed P, Boyle J, Kirkpatrick JP, Mak KS, Shih HA, Engelman A, Roberge D, Arvold ND, Alexander B, Awad MM, Contessa J, Chiang V, Hardie J, Ma D, Lou E, Sperduto W, Mehta MP. Sperduto PW, et al. Among authors: awad mm. Int J Radiat Oncol Biol Phys. 2016 Oct 1;96(2):406-413. doi: 10.1016/j.ijrobp.2016.06.006. Epub 2016 Jun 14. Int J Radiat Oncol Biol Phys. 2016. PMID: 27598807 Free PMC article.

76

Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer.

Bahcall M, Sim T, Paweletz CP, Patel JD, Alden RS, Kuang Y, Sacher AG, Kim ND, Lydon CA, Awad MM, Jaklitsch MT, Sholl LM, Jänne PA, Oxnard GR. Bahcall M, et al. Among authors: awad mm. Cancer Discov. 2016 Dec;6(12):1334-1341. doi: 10.1158/2159-8290.CD-16-0686. Epub 2016 Sep 30. Cancer Discov. 2016. PMID: 27694386 Free PMC article.

77

Nishino M, Ramaiya NH, Chambers ES, Adeni AE, Hatabu H, Jänne PA, Hodi FS, Awad MM. Nishino M, et al. Among authors: awad mm. J Immunother Cancer. 2016 Dec 20;4:84. doi: 10.1186/s40425-016-0193-2. eCollection 2016. J Immunother Cancer. 2016. PMID: 28018599 Free PMC article.

78

Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry.

Gautschi O, Milia J, Filleron T, Wolf J, Carbone DP, Owen D, Camidge R, Narayanan V, Doebele RC, Besse B, Remon-Masip J, Janne PA, Awad MM, Peled N, Byoung CC, Karp DD, Van Den Heuvel M, Wakelee HA, Neal JW, Mok TSK, Yang JCH, Ou SI, Pall G, Froesch P, Zalcman G, Gandara DR, Riess JW, Velcheti V, Zeidler K, Diebold J, Früh M, Michels S, Monnet I, Popat S, Rosell R, Karachaliou N, Rothschild SI, Shih JY, Warth A, Muley T, Cabillic F, Mazières J, Drilon A. Gautschi O, et al. Among authors: awad mm. J Clin Oncol. 2017 May 1;35(13):1403-1410. doi: 10.1200/JCO.2016.70.9352. Epub 2017 Mar 13. J Clin Oncol. 2017. PMID: 28447912 Free PMC article.

79

Interleukin-17A Promotes Lung Tumor Progression through Neutrophil Attraction to Tumor Sites and Mediating Resistance to PD-1 Blockade.

Akbay EA, Koyama S, Liu Y, Dries R, Bufe LE, Silkes M, Alam MM, Magee DM, Jones R, Jinushi M, Kulkarni M, Carretero J, Wang X, Warner-Hatten T, Cavanaugh JD, Osa A, Kumanogoh A, Freeman GJ, Awad MM, Christiani DC, Bueno R, Hammerman PS, Dranoff G, Wong KK. Akbay EA, et al. Among authors: awad mm. J Thorac Oncol. 2017 Aug;12(8):1268-1279. doi: 10.1016/j.jtho.2017.04.017. Epub 2017 May 6. J Thorac Oncol. 2017. PMID: 28483607 Free PMC article.

80

Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring MET Exon 14 Mutations and Overcomes Mutation-mediated Resistance to Type I MET Inhibitors in Nonclinical Models.

Engstrom LD, Aranda R, Lee M, Tovar EA, Essenburg CJ, Madaj Z, Chiang H, Briere D, Hallin J, Lopez-Casas PP, Baños N, Menendez C, Hidalgo M, Tassell V, Chao R, Chudova DI, Lanman RB, Olson P, Bazhenova L, Patel SP, Graveel C, Nishino M, Shapiro GI, Peled N, Awad MM, Jänne PA, Christensen JG. Engstrom LD, et al. Among authors: awad mm. Clin Cancer Res. 2017 Nov 1;23(21):6661-6672. doi: 10.1158/1078-0432.CCR-17-1192. Epub 2017 Aug 1. Clin Cancer Res. 2017. PMID: 28765324 Clinical Trial.

81

Sarcoid-Like Granulomatosis of the Lung Related to Immune-Checkpoint Inhibitors: Distinct Clinical and Imaging Features of a Unique Immune-Related Adverse Event.

Nishino M, Sholl LM, Awad MM, Hatabu H, Armand P, Hodi FS. Nishino M, et al. Among authors: awad mm. Cancer Immunol Res. 2018 Jun;6(6):630-635. doi: 10.1158/2326-6066.CIR-17-0715. Epub 2018 Apr 5. Cancer Immunol Res. 2018. PMID: 29622582 Free PMC article.

82

Amplification of Wild-type KRAS Imparts Resistance to Crizotinib in MET Exon 14 Mutant Non-Small Cell Lung Cancer.

Bahcall M, Awad MM, Sholl LM, Wilson FH, Xu M, Wang S, Palakurthi S, Choi J, Ivanova EV, Leonardi GC, Ulrich BC, Paweletz CP, Kirschmeier PT, Watanabe M, Baba H, Nishino M, Nagy RJ, Lanman RB, Capelletti M, Chambers ES, Redig AJ, VanderLaan PA, Costa DB, Imamura Y, Jänne PA. Bahcall M, et al. Among authors: awad mm. Clin Cancer Res. 2018 Dec 1;24(23):5963-5976. doi: 10.1158/1078-0432.CCR-18-0876. Epub 2018 Aug 2. Clin Cancer Res. 2018. PMID: 30072474 Free PMC article.

83

Impact of BRAF Mutation Class on Disease Characteristics and Clinical Outcomes in BRAF-mutant Lung Cancer.

Dagogo-Jack I, Martinez P, Yeap BY, Ambrogio C, Ferris LA, Lydon C, Nguyen T, Jessop NA, Iafrate AJ, Johnson BE, Lennerz JK, Shaw AT, Awad MM. Dagogo-Jack I, et al. Among authors: awad mm. Clin Cancer Res. 2019 Jan 1;25(1):158-165. doi: 10.1158/1078-0432.CCR-18-2062. Epub 2018 Sep 17. Clin Cancer Res. 2019. PMID: 30224342

84

Authors' Response.

Cheng MP, Marty FM, Costa DB, Awad MM. Cheng MP, et al. Among authors: awad mm. J Thorac Oncol. 2018 Nov;13(11):e237. doi: 10.1016/j.jtho.2018.09.015. J Thorac Oncol. 2018. PMID: 30368420 Free article. No abstract available.

85

Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer.

Hellmann MD, Callahan MK, Awad MM, Calvo E, Ascierto PA, Atmaca A, Rizvi NA, Hirsch FR, Selvaggi G, Szustakowski JD, Sasson A, Golhar R, Vitazka P, Chang H, Geese WJ, Antonia SJ. Hellmann MD, et al. Among authors: awad mm. Cancer Cell. 2019 Feb 11;35(2):329. doi: 10.1016/j.ccell.2019.01.011. Cancer Cell. 2019. PMID: 30753829 Free article. No abstract available.

86

Pre-existing autoimmune disease and the risk of immune-related adverse events among patients receiving checkpoint inhibitors for cancer.

Kehl KL, Yang S, Awad MM, Palmer N, Kohane IS, Schrag D. Kehl KL, et al. Among authors: awad mm. Cancer Immunol Immunother. 2019 Jun;68(6):917-926. doi: 10.1007/s00262-019-02321-z. Epub 2019 Mar 15. Cancer Immunol Immunother. 2019. PMID: 30877325 Free PMC article.

87

Palliative Radiation Therapy for Vertebral Metastases and Metastatic Cord Compression in Patients Treated With Anti-PD-1 Therapy.

Fareed MM, Pike LRG, Bang A, Huynh MA, Taylor A, Spektor A, Awad MM, Ott PA, Krishnan M, Balboni TA, Schoenfeld JD. Fareed MM, et al. Among authors: awad mm. Front Oncol. 2019 Mar 29;9:199. doi: 10.3389/fonc.2019.00199. eCollection 2019. Front Oncol. 2019. PMID: 30984622 Free PMC article.

88

Imaging of Precision Therapy for Lung Cancer: Current State of the Art.

Park H, Sholl LM, Hatabu H, Awad MM, Nishino M. Park H, et al. Among authors: awad mm. Radiology. 2019 Oct;293(1):15-29. doi: 10.1148/radiol.2019190173. Epub 2019 Aug 6. Radiology. 2019. PMID: 31385753 Free PMC article. Review.

89

Harmonization of Tumor Mutational Burden Quantification and Association With Response to Immune Checkpoint Blockade in Non-Small-Cell Lung Cancer.

Vokes NI, Liu D, Ricciuti B, Jimenez-Aguilar E, Rizvi H, Dietlein F, He MX, Margolis CA, Elmarakeby HA, Girshman J, Adeni A, Sanchez-Vega F, Schultz N, Dahlberg S, Zehir A, Jänne PA, Nishino M, Umeton R, Sholl LM, Van Allen EM, Hellmann MD, Awad MM. Vokes NI, et al. Among authors: awad mm. JCO Precis Oncol. 2019;3:PO.19.00171. doi: 10.1200/PO.19.00171. Epub 2019 Nov 12. JCO Precis Oncol. 2019. PMID: 31832578 Free PMC article.

90

Safety of Immune Checkpoint Inhibitors in Patients With Pre-Existing Inflammatory Bowel Disease and Microscopic Colitis.

Grover S, Ruan AB, Srivoleti P, Giobbie-Hurder A, Braschi-Amirfarzan M, Srivastava A, Buchbinder EI, Ott PA, Kehl KL, Awad MM, Hodi FS, Rahma OE. Grover S, et al. Among authors: awad mm. JCO Oncol Pract. 2020 Sep;16(9):e933-e942. doi: 10.1200/JOP.19.00672. Epub 2020 May 13. JCO Oncol Pract. 2020. PMID: 32401685

91

Complete and prolonged response to anti-PD1 therapy in an ALK rearranged lung adenocarcinoma.

Baldacci S, Grégoire V, Patrucco E, Chiarle R, Jamme P, Wasielewski E, Descarpentries C, Copin MC, Awad MM, Cortot AB. Baldacci S, et al. Among authors: awad mm. Lung Cancer. 2020 Aug;146:366-369. doi: 10.1016/j.lungcan.2020.05.008. Epub 2020 May 27. Lung Cancer. 2020. PMID: 32553554

92

Turnaround Time of Plasma Next-Generation Sequencing in Thoracic Oncology Patients: A Quality Improvement Analysis.

Lee Y, Clark EW, Milan MSD, Champagne C, Michael KS, Awad MM, Barbie DA, Cheng ML, Kehl KL, Marcoux JP, Rabin MS, Rotow JK, Sands JM, Jänne PA, Oxnard GR. Lee Y, et al. Among authors: awad mm. JCO Precis Oncol. 2020 Sep 21;4:PO.20.00121. doi: 10.1200/PO.20.00121. eCollection 2020. JCO Precis Oncol. 2020. PMID: 33015530 Free PMC article.

93

Intrinsic Immunogenicity of Small Cell Lung Carcinoma Revealed by Its Cellular Plasticity.

Mahadevan NR, Knelson EH, Wolff JO, Vajdi A, Saigí M, Campisi M, Hong D, Thai TC, Piel B, Han S, Reinhold BB, Duke-Cohan JS, Poitras MJ, Taus LJ, Lizotte PH, Portell A, Quadros V, Santucci AD, Murayama T, Cañadas I, Kitajima S, Akitsu A, Fridrikh M, Watanabe H, Reardon B, Gokhale PC, Paweletz CP, Awad MM, Van Allen EM, Lako A, Wang XT, Chen B, Hong F, Sholl LM, Tolstorukov MY, Pfaff K, Jänne PA, Gjini E, Edwards R, Rodig S, Reinherz EL, Oser MG, Barbie DA. Mahadevan NR, et al. Among authors: awad mm. Cancer Discov. 2021 Aug;11(8):1952-1969. doi: 10.1158/2159-8290.CD-20-0913. Epub 2021 Mar 11. Cancer Discov. 2021. PMID: 33707236 Free PMC article.

94

SMARCA4 and Other SWItch/Sucrose NonFermentable Family Genomic Alterations in NSCLC: Clinicopathologic Characteristics and Outcomes to Immune Checkpoint Inhibition.

Alessi JV, Ricciuti B, Spurr LF, Gupta H, Li YY, Glass C, Nishino M, Cherniack AD, Lindsay J, Sharma B, Felt KD, Rodig SJ, Cheng ML, Sholl LM, Awad MM. Alessi JV, et al. Among authors: awad mm. J Thorac Oncol. 2021 Jul;16(7):1176-1187. doi: 10.1016/j.jtho.2021.03.024. J Thorac Oncol. 2021. PMID: 33845210 Free article.

95

Smoking History as a Potential Predictor of Immune Checkpoint Inhibitor Efficacy in Metastatic Non-Small Cell Lung Cancer.

Wang X, Ricciuti B, Alessi JV, Nguyen T, Awad MM, Lin X, Johnson BE, Christiani DC. Wang X, et al. Among authors: awad mm. J Natl Cancer Inst. 2021 Nov 29;113(12):1761-1769. doi: 10.1093/jnci/djab116. J Natl Cancer Inst. 2021. PMID: 34115098 Free PMC article.

96

High Sensitivity of Plasma Cell-Free DNA Genotyping in Cases With Evidence of Adequate Tumor Content.

Meador CB, Milan MSD, Hu EY, Awad MM, Rabin MS, Paweletz CP, Hartmaier R, Laus G, Oxnard GR. Meador CB, et al. Among authors: awad mm. JCO Precis Oncol. 2021 Jun 1;5:PO.20.00420. doi: 10.1200/PO.20.00420. eCollection 2021. JCO Precis Oncol. 2021. PMID: 34250382 Free PMC article.

97

Outcomes With Pembrolizumab Plus Platinum-Based Chemotherapy for Patients With NSCLC and Stable Brain Metastases: Pooled Analysis of KEYNOTE-021, -189, and -407.

Powell SF, Rodríguez-Abreu D, Langer CJ, Tafreshi A, Paz-Ares L, Kopp HG, Rodríguez-Cid J, Kowalski DM, Cheng Y, Kurata T, Awad MM, Lin J, Zhao B, Pietanza MC, Piperdi B, Garassino MC. Powell SF, et al. Among authors: awad mm. J Thorac Oncol. 2021 Nov;16(11):1883-1892. doi: 10.1016/j.jtho.2021.06.020. Epub 2021 Jul 12. J Thorac Oncol. 2021. PMID: 34265431 Free article.

98

Predictors of Rheumatic Immune-Related Adverse Events and De Novo Inflammatory Arthritis After Immune Checkpoint Inhibitor Treatment for Cancer.

Cunningham-Bussel A, Wang J, Prisco LC, Martin LW, Vanni KMM, Zaccardelli A, Nasrallah M, Gedmintas L, MacFarlane LA, Shadick NA, Awad MM, Rahma O, LeBoeuf NR, Gravallese EM, Sparks JA. Cunningham-Bussel A, et al. Among authors: awad mm. Arthritis Rheumatol. 2022 Mar;74(3):527-540. doi: 10.1002/art.41949. Epub 2022 Jan 25. Arthritis Rheumatol. 2022. PMID: 34397169 Free PMC article.

99

Care disruptions among patients with lung cancer: A COVID-19 and cancer outcomes study.

Bhalla S, Bakouny Z, Schmidt AL, Labaki C, Steinharter JA, Tremblay DA, Awad MM, Kessler AJ, Haddad RI, Evans M, Busser F, Wotman M, Curran CR, Zimmerman BS, Bouchard G, Jun T, Nuzzo PV, Qin Q, Hirsch L, Feld J, Kelleher KM, Seidman D, Huang HH, Anderson-Keightly HM, El Zarif T, Abou Alaiwi S, Rosenbloom TD, Stewart PS, Galsky MD, Choueiri TK, Doroshow DB. Bhalla S, et al. Among authors: awad mm. Lung Cancer. 2021 Oct;160:78-83. doi: 10.1016/j.lungcan.2021.07.002. Epub 2021 Jul 16. Lung Cancer. 2021. PMID: 34461400 Free PMC article.

100

Meta-Analysis of PD-L1 Expression As a Predictor of Survival After Checkpoint Blockade.

Arfè A, Fell G, Alexander B, Awad MM, Rodig SJ, Trippa L, Schoenfeld JD. Arfè A, et al. Among authors: awad mm. JCO Precis Oncol. 2020 Nov;4:1196-1206. doi: 10.1200/PO.20.00150. JCO Precis Oncol. 2020. PMID: 35050777

101

Comparative Analysis and Isoform-Specific Therapeutic Vulnerabilities of KRAS Mutations in Non-Small Cell Lung Cancer.

Ricciuti B, Son J, Okoro JJ, Mira A, Patrucco E, Eum Y, Wang X, Paranal R, Wang H, Lin M, Haikala HM, Li J, Xu Y, Alessi JV, Chhoeu C, Redig AJ, Köhler J, Dholakia KH, Chen Y, Richard E, Nokin MJ, Santamaria D, Gokhale PC, Awad MM, Jänne PA, Ambrogio C. Ricciuti B, et al. Among authors: awad mm. Clin Cancer Res. 2022 Apr 14;28(8):1640-1650. doi: 10.1158/1078-0432.CCR-21-2719. Clin Cancer Res. 2022. PMID: 35091439 Free PMC article.

102

Prognostic effect of body mass index in patients with advanced NSCLC treated with chemoimmunotherapy combinations.

Cortellini A, Ricciuti B, Vaz VR, Soldato D, Alessi JV, Dall'Olio FG, Banna GL, Muthuramalingam S, Chan S, Majem M, Piedra A, Lamberti G, Andrini E, Addeo A, Friedlaender A, Facchinetti F, Gorría T, Mezquita L, Hoton D, Valerie L, Nana FA, Artingstall J, Comins C, Di Maio M, Caglio A, Cave J, McKenzie H, Newsom-Davis T, Evans JS, Tiseo M, D'Alessio A, Fulgenzi CAM, Besse B, Awad MM, Pinato DJ. Cortellini A, et al. Among authors: awad mm. J Immunother Cancer. 2022 Feb;10(2):e004374. doi: 10.1136/jitc-2021-004374. J Immunother Cancer. 2022. PMID: 35173031 Free PMC article.

103

Variation in targetable genomic alterations in non-small cell lung cancer by genetic ancestry, sex, smoking history, and histology.

Adib E, Nassar AH, Abou Alaiwi S, Groha S, Akl EW, Sholl LM, Michael KS, Awad MM, Jӓnne PA, Gusev A, Kwiatkowski DJ. Adib E, et al. Among authors: awad mm. Genome Med. 2022 Apr 15;14(1):39. doi: 10.1186/s13073-022-01041-x. Genome Med. 2022. PMID: 35428358 Free PMC article.

104

Reply to Kus and Aktas.

Ricciuti B, Awad MM. Ricciuti B, et al. Among authors: awad mm. J Thorac Oncol. 2022 Jun;17(6):e64-e65. doi: 10.1016/j.jtho.2022.04.004. J Thorac Oncol. 2022. PMID: 35623684 Free article. No abstract available.

105

Oncology clinical trial disruption during the COVID-19 pandemic: a COVID-19 and cancer outcomes study.

Bakouny Z, Labaki C, Bhalla S, Schmidt AL, Steinharter JA, Cocco J, Tremblay DA, Awad MM, Kessler A, Haddad RI, Evans M, Busser F, Wotman M, Curran CR, Zimmerman BS, Bouchard G, Jun T, Nuzzo PV, Qin Q, Hirsch L, Feld J, Kelleher KM, Seidman D, Huang H, Anderson-Keightly HM, El Zarif T, Alaiwi SA, Champagne C, Rosenbloom TD, Stewart PS, Johnson BE, Trinh Q, Tolaney SM, Galsky MD, Choueiri TK, Doroshow DB. Bakouny Z, et al. Among authors: awad mm. Ann Oncol. 2022 Aug;33(8):836-844. doi: 10.1016/j.annonc.2022.04.071. Epub 2022 Jun 14. Ann Oncol. 2022. PMID: 35715285 Free PMC article.

106

Corrigendum: Selective Histone Deacetylase Inhibitor ACY-241 (Citarinostat) Plus Nivolumab in Advanced Non-Small Cell Lung Cancer: Results From a Phase Ib Study.

Awad MM, Le Bruchec Y, Lu B, Ye J, Miller JA, Lizotte PH, Cavanaugh ME, Rode AJ, Dumitru CD, Spira A. Awad MM, et al. Front Oncol. 2022 Jun 7;12:889996. doi: 10.3389/fonc.2022.889996. eCollection 2022. Front Oncol. 2022. PMID: 35747830 Free PMC article.

107

A multicentre study of pembrolizumab time-of-day infusion patterns and clinical outcomes in non-small-cell lung cancer: too soon to promote morning infusions.

Cortellini A, Barrichello APC, Alessi JV, Ricciuti B, Vaz VR, Newsom-Davis T, Evans JS, Lamberti G, Pecci F, Viola P, D'Alessio A, Fulgenzi CAM, Awad MM, Pinato DJ. Cortellini A, et al. Among authors: awad mm. Ann Oncol. 2022 Nov;33(11):1202-1204. doi: 10.1016/j.annonc.2022.07.1851. Epub 2022 Aug 8. Ann Oncol. 2022. PMID: 35953005 Free article. No abstract available.

108

Association of Machine Learning-Based Assessment of Tumor-Infiltrating Lymphocytes on Standard Histologic Images With Outcomes of Immunotherapy in Patients With NSCLC.

Rakaee M, Adib E, Ricciuti B, Sholl LM, Shi W, Alessi JV, Cortellini A, Fulgenzi CAM, Viola P, Pinato DJ, Hashemi S, Bahce I, Houda I, Ulas EB, Radonic T, Väyrynen JP, Richardsen E, Jamaly S, Andersen S, Donnem T, Awad MM, Kwiatkowski DJ. Rakaee M, et al. Among authors: awad mm. JAMA Oncol. 2023 Jan 1;9(1):51-60. doi: 10.1001/jamaoncol.2022.4933. JAMA Oncol. 2023. PMID: 36394839 Free PMC article.

109

Atezolizumab Plus Bevacizumab in TMB-High Non-Small Cell Lung Cancers-The Hunt for Predictive Biomarkers to Optimize Treatment Selection.

Ricciuti B, Awad MM. Ricciuti B, et al. Among authors: awad mm. JAMA Oncol. 2023 Mar 1;9(3):353-354. doi: 10.1001/jamaoncol.2022.5801. JAMA Oncol. 2023. PMID: 36520420 No abstract available.

110

Increased Tumor Mutation Burden Levels and Sensitivity of Non-Small Cell Lung Cancer to PD-L1 Blockade-Reply.

Ricciuti B, Wang X, Awad MM. Ricciuti B, et al. Among authors: awad mm. JAMA Oncol. 2023 Apr 1;9(4):570-571. doi: 10.1001/jamaoncol.2022.7589. JAMA Oncol. 2023. PMID: 36729462 Free PMC article. No abstract available.

111

Incidence of Brain Metastases and Preliminary Evidence of Intracranial Activity With Sotorasib in Patients With KRAS^G12C-Mutant Non-Small-Cell Lung Cancer.

Lamberti G, Aizer A, Ricciuti B, Alessi JV, Pecci F, Tseng SC, Sholl LM, Nishino M, Awad MM. Lamberti G, et al. Among authors: awad mm. JCO Precis Oncol. 2023 Feb;7:e2200621. doi: 10.1200/PO.22.00621. JCO Precis Oncol. 2023. PMID: 36809054 Free PMC article. No abstract available.

112

[No title available]

[No authors listed] [No authors listed] PMID: 36815433

113

Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC.

Negrao MV, Araujo HA, Lamberti G, Cooper AJ, Akhave NS, Zhou T, Delasos L, Hicks JK, Aldea M, Minuti G, Hines J, Aredo JV, Dennis MJ, Chakrabarti T, Scott SC, Bironzo P, Scheffler M, Christopoulos P, Stenzinger A, Riess JW, Kim SY, Goldberg SB, Li M, Wang Q, Qing Y, Ni Y, Do MT, Lee R, Ricciuti B, Alessi JV, Wang J, Resuli B, Landi L, Tseng SC, Nishino M, Digumarthy SR, Rinsurongkawong W, Rinsurongkawong V, Vaporciyan AA, Blumenschein GR, Zhang J, Owen DH, Blakely CM, Mountzios G, Shu CA, Bestvina CM, Garassino MC, Marrone KA, Gray JE, Patel SP, Cummings AL, Wakelee HA, Wolf J, Scagliotti GV, Cappuzzo F, Barlesi F, Patil PD, Drusbosky L, Gibbons DL, Meric-Bernstam F, Lee JJ, Heymach JV, Hong DS, Heist RS, Awad MM, Skoulidis F. Negrao MV, et al. Among authors: awad mm. Cancer Discov. 2023 Jul 7;13(7):1556-1571. doi: 10.1158/2159-8290.CD-22-1420. Cancer Discov. 2023. PMID: 37068173 Free PMC article.

114

Clinicopathologic, Genomic, and Immunophenotypic Landscape of ATM Mutations in Non-Small Cell Lung Cancer.

Ricciuti B, Elkrief A, Alessi J, Wang X, Li Y, Gupta H, Muldoon DM, Bertram AA, Pecci F, Lamberti G, Di Federico A, Barrichello A, Vaz VR, Gandhi M, Lee E, Shapiro GI, Park H, Nishino M, Lindsay J, Felt KD, Sharma B, Cherniack AD, Rodig S, Gomez DR, Shaverdian N, Rakaee M, Bandlamudi C, Ladanyi M, Janne PA, Schoenfeld AJ, Sholl LM, Awad MM, Cheng ML. Ricciuti B, et al. Among authors: awad mm. Clin Cancer Res. 2023 Jul 5;29(13):2540-2550. doi: 10.1158/1078-0432.CCR-22-3413. Clin Cancer Res. 2023. PMID: 37097610 Free PMC article.

115

Advanced non-small-cell lung cancer treated with first-line pembrolizumab plus chemotherapy: tumor response dynamics as a marker for survival.

Nishino M, Wang X, Ricciuti B, Tseng SC, Park H, Alessi JV, Vaz VR, Hatabu H, Lin X, Christiani DC, Awad MM. Nishino M, et al. Among authors: awad mm. Eur Radiol. 2023 Oct;33(10):7284-7293. doi: 10.1007/s00330-023-09658-1. Epub 2023 Apr 26. Eur Radiol. 2023. PMID: 37099174

116

Impact of Aneuploidy and Chromosome 9p Loss on Tumor Immune Microenvironment and Immune Checkpoint Inhibitor Efficacy in NSCLC.

Alessi JV, Wang X, Elkrief A, Ricciuti B, Li YY, Gupta H, Spurr LF, Rizvi H, Luo J, Pecci F, Lamberti G, Recondo G, Venkatraman D, Di Federico A, Gandhi MM, Vaz VR, Nishino M, Sholl LM, Cherniack AD, Ladanyi M, Price A, Richards AL, Donoghue M, Lindsay J, Sharma B, Turner MM, Pfaff KL, Felt KD, Rodig SJ, Lin X, Meyerson ML, Johnson BE, Christiani DC, Schoenfeld AJ, Awad MM. Alessi JV, et al. Among authors: awad mm. J Thorac Oncol. 2023 Nov;18(11):1524-1537. doi: 10.1016/j.jtho.2023.05.019. Epub 2023 May 27. J Thorac Oncol. 2023. PMID: 37247843 Free PMC article.

117

Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non-Small Cell Lung Cancer.

Thummalapalli R, Ricciuti B, Bandlamudi C, Muldoon D, Rizvi H, Elkrief A, Luo J, Alessi JV, Pecci F, Lamberti G, Di Federico A, Hong L, Zhang J, Heymach JV, Gibbons DL, Plodkowski AJ, Ravichandran V, Donoghue MTA, Vanderbilt C, Ladanyi M, Rudin CM, Kris MG, Riely GJ, Chaft JE, Hellmann MD, Vokes NI, Awad MM, Schoenfeld AJ. Thummalapalli R, et al. Among authors: awad mm. Clin Cancer Res. 2023 Nov 1;29(21):4408-4418. doi: 10.1158/1078-0432.CCR-23-1207. Clin Cancer Res. 2023. PMID: 37432985 Free PMC article.

118

Impact of TMB/PD-L1 expression and pneumonitis on chemoradiation and durvalumab response in stage III NSCLC.

Alessi JV, Ricciuti B, Wang X, Pecci F, Di Federico A, Lamberti G, Elkrief A, Rodig SJ, Lebow ES, Eicholz JE, Thor M, Rimner A, Schoenfeld AJ, Chaft JE, Johnson BE, Gomez DR, Awad MM, Shaverdian N. Alessi JV, et al. Among authors: awad mm. Nat Commun. 2023 Jul 15;14(1):4238. doi: 10.1038/s41467-023-39874-8. Nat Commun. 2023. PMID: 37454214 Free PMC article.

119

Efficacy of PD-(L)1 blockade monotherapy compared with PD-(L)1 blockade plus chemotherapy in first-line PD-L1-positive advanced lung adenocarcinomas: a cohort study.

Elkrief A, Alessi JMV, Ricciuti B, Brown S, Rizvi H, Preeshagul IR, Wang X, Pecci F, Di Federico A, Lamberti G, Egger JV, Chaft JE, Rudin CM, Riely GJ, Kris MG, Ladanyi M, Chen Y, Hellmann MD, Shen R, Awad MM, Schoenfeld AJ. Elkrief A, et al. Among authors: awad mm. J Immunother Cancer. 2023 Jul;11(7):e006994. doi: 10.1136/jitc-2023-006994. J Immunother Cancer. 2023. PMID: 37487667 Free PMC article.

120

Outcomes of Combination Platinum-Doublet Chemotherapy and Anti-PD(L)-1 Blockade in KRASG12C-Mutant Non-Small Cell Lung Cancer.

Elkrief A, Riccuiti B, Alessi JV, Fei T, Kalvin HL, Egger JV, Rizvi H, Thummalapalli R, Lamberti G, Plodkowski A, Hellmann MD, Kris MG, Arcila ME, Baine MK, Rudin CM, Lito P, Ladanyi M, Schoenfeld AJ, Riely GJ, Awad MM, Arbour KC. Elkrief A, et al. Among authors: awad mm. Oncologist. 2023 Nov 2;28(11):978-985. doi: 10.1093/oncolo/oyad197. Oncologist. 2023. PMID: 37589215 Free PMC article.

121

Multi-institutional analysis of aneuploidy and outcomes to chemoradiation and durvalumab in stage III non-small cell lung cancer.

Alessi JV, Price A, Richards AL, Ricciuti B, Wang X, Elkrief A, Pecci F, Di Federico A, Gandhi MM, Lebow ES, Santos PMG, Thor M, Rimner A, Schoenfeld AJ, Chaft JE, Johnson BE, Gomez DR, Awad MM, Shaverdian N. Alessi JV, et al. Among authors: awad mm. J Immunother Cancer. 2023 Nov;11(11):e007618. doi: 10.1136/jitc-2023-007618. J Immunother Cancer. 2023. PMID: 37914383 Free PMC article.

122

Genomic and Immunophenotypic Landscape of Acquired Resistance to PD-(L)1 Blockade in Non-Small-Cell Lung Cancer.

Ricciuti B, Lamberti G, Puchala SR, Mahadevan NR, Lin JR, Alessi JV, Chowdhury A, Li YY, Wang X, Spurr L, Pecci F, Di Federico A, Venkatraman D, Barrichello AP, Gandhi M, Vaz VR, Pangilinan AJ, Haradon D, Lee E, Gupta H, Pfaff KL, Welsh EL, Nishino M, Cherniack AD, Johnson BE, Weirather JL, Dryg ID, Rodig SJ, Sholl LM, Sorger P, Santagata S, Umeton R, Awad MM. Ricciuti B, et al. Among authors: awad mm. J Clin Oncol. 2024 Apr 10;42(11):1311-1321. doi: 10.1200/JCO.23.00580. Epub 2024 Jan 11. J Clin Oncol. 2024. PMID: 38207230

123

Epitope mapping of spontaneous autoantibodies to anaplastic lymphoma kinase (ALK) in non-small cell lung cancer.

Awad MM, Mastini C, Blasco RB, Mologni L, Voena C, Mussolin L, Mach SL, Adeni AE, Lydon CA, Sholl LM, Jänne PA, Chiarle R. Awad MM, et al. Oncotarget. 2017 Sep 23;8(54):92265-92274. doi: 10.18632/oncotarget.21182. eCollection 2017 Nov 3. Oncotarget. 2017. PMID: 29190913 Free PMC article.

124

Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC.

Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Kurata T, Chiappori A, Lee KH, de Wit M, Cho BC, Bourhaba M, Quantin X, Tokito T, Mekhail T, Planchard D, Kim YC, Karapetis CS, Hiret S, Ostoros G, Kubota K, Gray JE, Paz-Ares L, de Castro Carpeño J, Faivre-Finn C, Reck M, Vansteenkiste J, Spigel DR, Wadsworth C, Melillo G, Taboada M, Dennis PA, Özgüroğlu M; PACIFIC Investigators. Antonia SJ, et al. N Engl J Med. 2018 Dec 13;379(24):2342-2350. doi: 10.1056/NEJMoa1809697. Epub 2018 Sep 25. N Engl J Med. 2018. PMID: 30280658 Free article. Clinical Trial.

125

Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration.

Drilon A, Clark JW, Weiss J, Ou SI, Camidge DR, Solomon BJ, Otterson GA, Villaruz LC, Riely GJ, Heist RS, Awad MM, Shapiro GI, Satouchi M, Hida T, Hayashi H, Murphy DA, Wang SC, Li S, Usari T, Wilner KD, Paik PK. Drilon A, et al. Among authors: awad mm. Nat Med. 2020 Jan;26(1):47-51. doi: 10.1038/s41591-019-0716-8. Epub 2020 Jan 13. Nat Med. 2020. PMID: 31932802 Free PMC article.

126

Molecular Mechanisms of Acquired Resistance to MET Tyrosine Kinase Inhibitors in Patients with MET Exon 14-Mutant NSCLC.

Recondo G, Bahcall M, Spurr LF, Che J, Ricciuti B, Leonardi GC, Lo YC, Li YY, Lamberti G, Nguyen T, Milan MSD, Venkatraman D, Umeton R, Paweletz CP, Albayrak A, Cherniack AD, Price KS, Fairclough SR, Nishino M, Sholl LM, Oxnard GR, Jänne PA, Awad MM. Recondo G, et al. Among authors: awad mm. Clin Cancer Res. 2020 Jun 1;26(11):2615-2625. doi: 10.1158/1078-0432.CCR-19-3608. Epub 2020 Feb 7. Clin Cancer Res. 2020. PMID: 32034073

127

Tumor volume dynamics and tumor growth rate in ALK-rearranged advanced non-small-cell lung cancer treated with crizotinib.

Nishino M, Hida T, Kravets S, Dahlberg SE, Lydon CA, Hatabu H, Johnson BE, Awad MM. Nishino M, et al. Among authors: awad mm. Eur J Radiol Open. 2020 Jan 28;7:100210. doi: 10.1016/j.ejro.2019.12.004. eCollection 2020. Eur J Radiol Open. 2020. PMID: 33102632 Free PMC article.

128

Axillary Lymphadenopathy After Coronavirus Disease 2019 Vaccinations in Patients With Thoracic Malignancy: Incidence, Predisposing Factors, and Imaging Characteristics.

Nishino M, Hatabu H, Ricciuti B, Vaz V, Michael K, Awad MM. Nishino M, et al. Among authors: awad mm. J Thorac Oncol. 2022 Jan;17(1):154-159. doi: 10.1016/j.jtho.2021.08.761. Epub 2021 Sep 29. J Thorac Oncol. 2022. PMID: 34506955 Free PMC article.

129

Clonal KEAP1 mutations with loss of heterozygosity share reduced immunotherapy efficacy and low immune cell infiltration in lung adenocarcinoma.

Scalera S, Ricciuti B, Mazzotta M, Calonaci N, Alessi JV, Cipriani L, Bon G, Messina B, Lamberti G, Di Federico A, Pecci F, Milite S, Krasniqi E, Barba M, Vici P, Vecchione A, De Nicola F, Ciuffreda L, Goeman F, Fanciulli M, Buglioni S, Pescarmona E, Sharma B, Felt KD, Lindsay J, Rodig SJ, De Maria R, Caravagna G, Cappuzzo F, Ciliberto G, Awad MM, Maugeri-Saccà M. Scalera S, et al. Among authors: awad mm. Ann Oncol. 2023 Mar;34(3):275-288. doi: 10.1016/j.annonc.2022.12.002. Epub 2022 Dec 13. Ann Oncol. 2023. PMID: 36526124 Free article.

130

Park H, Hata A, Hatabu H, Ricciuti B, Awad M, Nishino M. Park H, et al. Cancers (Basel). 2023 Jan 20;15(3):649. doi: 10.3390/cancers15030649. Cancers (Basel). 2023. PMID: 36765606 Free PMC article.

131

ALK peptide vaccination restores the immunogenicity of ALK-rearranged non-small cell lung cancer.

Mota I, Patrucco E, Mastini C, Mahadevan NR, Thai TC, Bergaggio E, Cheong TC, Leonardi G, Karaca-Atabay E, Campisi M, Poggio T, Menotti M, Ambrogio C, Longo DL, Klaeger S, Keshishian H, Sztupinszki ZM, Szallasi Z, Keskin DB, Duke-Cohan JS, Reinhold B, Carr SA, Wu CJ, Moynihan KD, Irvine DJ, Barbie DA, Reinherz EL, Voena C, Awad MM, Blasco RB, Chiarle R. Mota I, et al. Among authors: awad mm. Nat Cancer. 2023 Jul;4(7):1016-1035. doi: 10.1038/s43018-023-00591-2. Epub 2023 Jul 10. Nat Cancer. 2023. PMID: 37430060

132

Amplification of Wild-Type RET Represents a Novel Molecular Subtype of Several Cancer Types With Clinical Response to Selpercatinib.

Gandhi MM, Ricciuti B, Harada G, Repetto M, Gildenberg MS, Singh A, Li YY, Gagné A, Wang X, Aizer A, Fitzgerald K, Nishino M, Alessi J, Pecci F, Di Federico A, Fisch A, Drilon A, Nardi V, Sholl L, Awad MM, Rotow J. Gandhi MM, et al. Among authors: awad mm. JCO Precis Oncol. 2023 Sep;7:e2300295. doi: 10.1200/PO.23.00295. JCO Precis Oncol. 2023. PMID: 37972337

133

Influence of TP53 Comutation on the Tumor Immune Microenvironment and Clinical Outcomes With Immune Checkpoint Inhibitors in STK11-Mutant Non-Small-Cell Lung Cancer.

Naqash AR, Floudas CS, Aber E, Maoz A, Nassar AH, Adib E, Choucair K, Xiu J, Baca Y, Ricciuti B, Alessi JV, Awad MM, Kim C, Judd J, Raez LE, Lopes G, Nieva JJ, Borghaei H, Takebe N, Ma PC, Halmos B, Kwiatkowski DJ, Liu SV, Mamdani H. Naqash AR, et al. Among authors: awad mm. JCO Precis Oncol. 2024 Feb;8:e2300371. doi: 10.1200/PO.23.00371. JCO Precis Oncol. 2024. PMID: 38330261

134

Association of Baseline Tumor-Specific Neoantigens and CD8⁺ T-Cell Infiltration With Immune-Related Adverse Events Secondary to Immune Checkpoint Inhibitors.

Kerepesi C, Abushukair HM, Ricciuti B, Nassar AH, Adib E, Alessi JV, Pecci F, Rakaee M, Fadlullah MZH, Tőkés AM, Rodig SJ, Awad MM, Tan AC, Bakacs T, Naqash AR. Kerepesi C, et al. Among authors: awad mm. JCO Precis Oncol. 2024 Feb;8:e2300439. doi: 10.1200/PO.23.00439. JCO Precis Oncol. 2024. PMID: 38330262

135

Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients.

De Velasco G, Je Y, Bossé D, Awad MM, Ott PA, Moreira RB, Schutz F, Bellmunt J, Sonpavde GP, Hodi FS, Choueiri TK. De Velasco G, et al. Among authors: awad mm. Cancer Immunol Res. 2017 Apr;5(4):312-318. doi: 10.1158/2326-6066.CIR-16-0237. Epub 2017 Feb 28. Cancer Immunol Res. 2017. PMID: 28246107 Free PMC article.

136

An Acquired NRAS Q61K Mutation in BRAF V600E-Mutant Lung Adenocarcinoma Resistant to Dabrafenib Plus Trametinib.

Abravanel DL, Nishino M, Sholl LM, Ambrogio C, Awad MM. Abravanel DL, et al. Among authors: awad mm. J Thorac Oncol. 2018 Aug;13(8):e131-e133. doi: 10.1016/j.jtho.2018.03.026. Epub 2018 Apr 6. J Thorac Oncol. 2018. PMID: 29631033 Free PMC article. No abstract available.

137

Prevalence and Tolerance of Prognostic Uncertainty Among Thoracic Oncologists.

Habib AR, Chen R, Magnavita ES, Jaung T, Awad MM, Odejide O, Abel GA. Habib AR, et al. Among authors: awad mm. Oncologist. 2021 Aug;26(8):e1480-e1482. doi: 10.1002/onco.13788. Epub 2021 Apr 30. Oncologist. 2021. PMID: 33844365 Free PMC article.

138

Acquired Resistance to KRAS^G12C Inhibition in Cancer.

Awad MM, Liu S, Rybkin II, Arbour KC, Dilly J, Zhu VW, Johnson ML, Heist RS, Patil T, Riely GJ, Jacobson JO, Yang X, Persky NS, Root DE, Lowder KE, Feng H, Zhang SS, Haigis KM, Hung YP, Sholl LM, Wolpin BM, Wiese J, Christiansen J, Lee J, Schrock AB, Lim LP, Garg K, Li M, Engstrom LD, Waters L, Lawson JD, Olson P, Lito P, Ou SI, Christensen JG, Jänne PA, Aguirre AJ. Awad MM, et al. N Engl J Med. 2021 Jun 24;384(25):2382-2393. doi: 10.1056/NEJMoa2105281. N Engl J Med. 2021. PMID: 34161704 Free PMC article.

139

Radiation Recall Pneumonitis on FDG PET/CT Triggered by COVID-19 Vaccination.

Hughes NM, Hammer MM, Awad MM, Jacene HA. Hughes NM, et al. Among authors: awad mm. Clin Nucl Med. 2022 Mar 1;47(3):e281-e283. doi: 10.1097/RLU.0000000000003980. Clin Nucl Med. 2022. PMID: 34739397 Free PMC article.

140

Impact of Increasing PD-L1 Levels on Outcomes to PD-1/PD-L1 Inhibition in Patients With NSCLC: A Pooled Analysis of 11 Prospective Clinical Trials.

Vallejo J, Singh H, Larkins E, Drezner N, Ricciuti B, Mishra-Kalyani P, Tang S, Beaver JA, Awad MM. Vallejo J, et al. Among authors: awad mm. Oncologist. 2024 Feb 13:oyae006. doi: 10.1093/oncolo/oyae006. Online ahead of print. Oncologist. 2024. PMID: 38349736 Free article.

141

Cytotoxic T Cells in PD-L1-Positive Malignant Pleural Mesotheliomas Are Counterbalanced by Distinct Immunosuppressive Factors.

Awad MM, Jones RE, Liu H, Lizotte PH, Ivanova EV, Kulkarni M, Herter-Sprie GS, Liao X, Santos AA, Bittinger MA, Keogh L, Koyama S, Almonte C, English JM, Barlow J, Richards WG, Barbie DA, Bass AJ, Rodig SJ, Hodi FS, Wucherpfennig KW, Jänne PA, Sholl LM, Hammerman PS, Wong KK, Bueno R. Awad MM, et al. Cancer Immunol Res. 2016 Dec;4(12):1038-1048. doi: 10.1158/2326-6066.CIR-16-0171. Epub 2016 Nov 14. Cancer Immunol Res. 2016. PMID: 27856426

142

False-Positive Plasma Genotyping Due to Clonal Hematopoiesis.

Hu Y, Ulrich BC, Supplee J, Kuang Y, Lizotte PH, Feeney NB, Guibert NM, Awad MM, Wong KK, Jänne PA, Paweletz CP, Oxnard GR. Hu Y, et al. Among authors: awad mm. Clin Cancer Res. 2018 Sep 15;24(18):4437-4443. doi: 10.1158/1078-0432.CCR-18-0143. Epub 2018 Mar 22. Clin Cancer Res. 2018. PMID: 29567812

143

BRAF-Mutant Pulmonary Langerhans Cell Histiocytosis Mimicking Recurrence of Early-Stage KRAS-Mutant Lung Adenocarcinoma.

Alden SL, Swanson SJ, Nishino M, Sholl LM, Awad MM. Alden SL, et al. Among authors: awad mm. JTO Clin Res Rep. 2020 Dec 3;2(2):100127. doi: 10.1016/j.jtocrr.2020.100127. eCollection 2021 Feb. JTO Clin Res Rep. 2020. PMID: 34589987 Free PMC article. No abstract available.

144

Germline variants associated with toxicity to immune checkpoint blockade.

Groha S, Alaiwi SA, Xu W, Naranbhai V, Nassar AH, Bakouny Z, El Zarif T, Saliby RM, Wan G, Rajeh A, Adib E, Nuzzo PV, Schmidt AL, Labaki C, Ricciuti B, Alessi JV, Braun DA, Shukla SA, Keenan TE, Van Allen E, Awad MM, Manos M, Rahma O, Zubiri L, Villani AC, Fairfax B, Hammer C, Khan Z, Reynolds K, Semenov Y, Schrag D, Kehl KL, Freedman ML, Choueiri TK, Gusev A. Groha S, et al. Among authors: awad mm. Nat Med. 2022 Dec;28(12):2584-2591. doi: 10.1038/s41591-022-02094-6. Epub 2022 Dec 16. Nat Med. 2022. PMID: 36526723 Free PMC article.

145

Letter to the Editor: Reply to Kus and Aktas.

Alessi JV, Awad MM. Alessi JV, et al. Among authors: awad mm. J Thorac Oncol. 2023 Aug;18(8):e84-e85. doi: 10.1016/j.jtho.2023.05.018. J Thorac Oncol. 2023. PMID: 37479334 No abstract available.

146

Programmed Death Ligand-1 and Tumor Mutation Burden Testing of Patients With Lung Cancer for Selection of Immune Checkpoint Inhibitor Therapies: Guideline From the College of American Pathologists, Association for Molecular Pathology, International Association for the Study of Lung Cancer, Pulmonary Pathology Society, and LUNGevity Foundation.

Sholl LM, Awad M, Basu Roy U, Beasley MB, Cartun RW, Hwang DM, Kalemkerian G, Lopez-Rios F, Mino-Kenudson M, Paintal A, Reid K, Ritterhouse L, Souter LA, Swanson PE, Ventura CB, Furtado LV. Sholl LM, et al. Arch Pathol Lab Med. 2024 Apr 16. doi: 10.5858/arpa.2023-0536-CP. Online ahead of print. Arch Pathol Lab Med. 2024. PMID: 38625026 Free article.

147

BRAF Mutation Class and Clinical Outcomes-Response.

Dagogo-Jack I, Awad MM, Shaw AT. Dagogo-Jack I, et al. Among authors: awad mm. Clin Cancer Res. 2019 May 15;25(10):3189. doi: 10.1158/1078-0432.CCR-19-0422. Clin Cancer Res. 2019. PMID: 31092613 No abstract available.

148

Treatment-Induced Tumor Dormancy through YAP-Mediated Transcriptional Reprogramming of the Apoptotic Pathway.

Kurppa KJ, Liu Y, To C, Zhang T, Fan M, Vajdi A, Knelson EH, Xie Y, Lim K, Cejas P, Portell A, Lizotte PH, Ficarro SB, Li S, Chen T, Haikala HM, Wang H, Bahcall M, Gao Y, Shalhout S, Boettcher S, Shin BH, Thai T, Wilkens MK, Tillgren ML, Mushajiang M, Xu M, Choi J, Bertram AA, Ebert BL, Beroukhim R, Bandopadhayay P, Awad MM, Gokhale PC, Kirschmeier PT, Marto JA, Camargo FD, Haq R, Paweletz CP, Wong KK, Barbie DA, Long HW, Gray NS, Jänne PA. Kurppa KJ, et al. Among authors: awad mm. Cancer Cell. 2020 Jan 13;37(1):104-122.e12. doi: 10.1016/j.ccell.2019.12.006. Cancer Cell. 2020. PMID: 31935369 Free PMC article.

149

Mammalian SWI/SNF Complex Genomic Alterations and Immune Checkpoint Blockade in Solid Tumors.

Abou Alaiwi S, Nassar AH, Xie W, Bakouny Z, Berchuck JE, Braun DA, Baca SC, Nuzzo PV, Flippot R, Mouhieddine TH, Spurr LF, Li YY, Li T, Flaifel A, Steinharter JA, Margolis CA, Vokes NI, Du H, Shukla SA, Cherniack AD, Sonpavde G, Haddad RI, Awad MM, Giannakis M, Hodi FS, Liu XS, Signoretti S, Kadoch C, Freedman ML, Kwiatkowski DJ, Van Allen EM, Choueiri TK. Abou Alaiwi S, et al. Among authors: awad mm. Cancer Immunol Res. 2020 Aug;8(8):1075-1084. doi: 10.1158/2326-6066.CIR-19-0866. Epub 2020 Apr 22. Cancer Immunol Res. 2020. PMID: 32321774 Free PMC article.

150

Letter to the Editor: Reply to Zhao, Wu, and Ma.

Alessi JV, Elkrief A, Ricciuti B, Schoenfeld AJ, Awad MM. Alessi JV, et al. Among authors: awad mm. J Thorac Oncol. 2023 Jun;18(6):e61-e62. doi: 10.1016/j.jtho.2023.03.018. J Thorac Oncol. 2023. PMID: 37210184 No abstract available.

151

Acquired resistance to crizotinib from a mutation in CD74-ROS1.

Awad MM, Engelman JA, Shaw AT. Awad MM, et al. N Engl J Med. 2013 Sep 19;369(12):1173. doi: 10.1056/NEJMc1309091. N Engl J Med. 2013. PMID: 24047072 No abstract available.

152

Tyrosine kinase gene rearrangements in epithelial malignancies.

Shaw AT, Hsu PP, Awad MM, Engelman JA. Shaw AT, et al. Among authors: awad mm. Nat Rev Cancer. 2013 Nov;13(11):772-87. doi: 10.1038/nrc3612. Epub 2013 Oct 17. Nat Rev Cancer. 2013. PMID: 24132104 Free PMC article. Review.

153

Fine needle aspirate flow cytometric phenotyping characterizes immunosuppressive nature of the mesothelioma microenvironment.

Lizotte PH, Jones RE, Keogh L, Ivanova E, Liu H, Awad MM, Hammerman PS, Gill RR, Richards WG, Barbie DA, Bass AJ, Bueno R, English JM, Bittinger M, Wong KK. Lizotte PH, et al. Among authors: awad mm. Sci Rep. 2016 Aug 19;6:31745. doi: 10.1038/srep31745. Sci Rep. 2016. PMID: 27539742 Free PMC article.

154

Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors.

Miao D, Margolis CA, Vokes NI, Liu D, Taylor-Weiner A, Wankowicz SM, Adeegbe D, Keliher D, Schilling B, Tracy A, Manos M, Chau NG, Hanna GJ, Polak P, Rodig SJ, Signoretti S, Sholl LM, Engelman JA, Getz G, Jänne PA, Haddad RI, Choueiri TK, Barbie DA, Haq R, Awad MM, Schadendorf D, Hodi FS, Bellmunt J, Wong KK, Hammerman P, Van Allen EM. Miao D, et al. Among authors: awad mm. Nat Genet. 2018 Sep;50(9):1271-1281. doi: 10.1038/s41588-018-0200-2. Epub 2018 Aug 27. Nat Genet. 2018. PMID: 30150660 Free PMC article.

155

Targeting MET Dysregulation in Cancer.

Recondo G, Che J, Jänne PA, Awad MM. Recondo G, et al. Among authors: awad mm. Cancer Discov. 2020 Jul;10(7):922-934. doi: 10.1158/2159-8290.CD-19-1446. Epub 2020 Jun 12. Cancer Discov. 2020. PMID: 32532746 Free PMC article. Review.

156

Cancer Care Disparities during the COVID-19 Pandemic: COVID-19 and Cancer Outcomes Study.

Schmidt AL, Bakouny Z, Bhalla S, Steinharter JA, Tremblay DA, Awad MM, Kessler AJ, Haddad RI, Evans M, Busser F, Wotman M, Curran CR, Zimmerman BS, Bouchard G, Jun T, Nuzzo PV, Qin Q, Hirsch L, Feld J, Kelleher KM, Seidman D, Huang HH, Anderson-Keightly HM, Abou Alaiwi S, Rosenbloom TD, Stewart PS, Galsky MD, Choueiri TK, Doroshow DB. Schmidt AL, et al. Among authors: awad mm. Cancer Cell. 2020 Dec 14;38(6):769-770. doi: 10.1016/j.ccell.2020.10.023. Epub 2020 Nov 3. Cancer Cell. 2020. PMID: 33176161 Free PMC article. No abstract available.

157

Twists and turns from "tumor in tumor" profiling: surveillance of chronic lymphocytic leukemia (CLL) leads to detection of a lung adenocarcinoma, whose genomic characterization alters the original hematologic diagnosis.

Terraf P, Sholl LM, Davids MS, Awad MM, Garcia EP, MacConaill LE, Dal Cin P, Kim A, Lindeman NI, Stachler M, Hwang DH, Dubuc AM. Terraf P, et al. Among authors: awad mm. Cold Spring Harb Mol Case Stud. 2021 Aug 2;7(4):a006089. doi: 10.1101/mcs.a006089. Print 2021 Aug. Cold Spring Harb Mol Case Stud. 2021. PMID: 34074652 Free PMC article.

158

Response to Hopkins, Kichenadasse, Logan, et al.

Wang X, Ricciuti B, Alessi JV, Nguyen T, Awad MM, Lin X, Johnson BE, Christiani DC. Wang X, et al. Among authors: awad mm. J Natl Cancer Inst. 2022 Mar 8;114(3):477-478. doi: 10.1093/jnci/djab161. J Natl Cancer Inst. 2022. PMID: 34450659 Free PMC article. No abstract available.

159

Leptomeningeal Response to Capmatinib After Progression on Crizotinib in a Patient With MET Exon 14-Mutant NSCLC.

Cravero P, Vaz N, Ricciuti B, Clifford SE, DiUbaldi G, Drevers D, Morton K, Rivenburgh RE, Nishino M, Awad MM. Cravero P, et al. Among authors: awad mm. JTO Clin Res Rep. 2020 Jul 1;1(4):100072. doi: 10.1016/j.jtocrr.2020.100072. eCollection 2020 Nov. JTO Clin Res Rep. 2020. PMID: 34589954 Free PMC article. No abstract available.

160

JNJ-64041757 (JNJ-757), a Live, Attenuated, Double-Deleted Listeria monocytogenes-Based Immunotherapy in Patients With NSCLC: Results From Two Phase 1 Studies.

Brahmer JR, Johnson ML, Cobo M, Viteri S, Sarto JC, Sukari A, Awad MM, Salgia R, Papadimitrakopoulou VA, Rajan A, Bandyopadhyay N, Allred AJ, Wade M, Mason GE, Zudaire E, Knoblauch RE, Stone N, Lorenzi MV, Hassan R. Brahmer JR, et al. Among authors: awad mm. JTO Clin Res Rep. 2020 Oct 5;2(2):100103. doi: 10.1016/j.jtocrr.2020.100103. eCollection 2021 Feb. JTO Clin Res Rep. 2020. PMID: 34589981 Free PMC article.

161

SPACEWALK: A Remote Participation Study of ALK Resistance Leveraging Plasma Cell-Free DNA Genotyping.

Lawrence MN, Tamen RM, Martinez P, Sable-Hunt A, Addario T, Barbour P, Shaffer T, Hosseini SA, Bertucci C, Lim LP, Hong F, Michael K, Simon GR, Riess JW, Awad MM, Oxnard GR. Lawrence MN, et al. Among authors: awad mm. JTO Clin Res Rep. 2021 Feb 3;2(4):100151. doi: 10.1016/j.jtocrr.2021.100151. eCollection 2021 Apr. JTO Clin Res Rep. 2021. PMID: 34590008 Free PMC article.

162

Abemaciclib in Combination With Pembrolizumab for Stage IV KRAS-Mutant or Squamous NSCLC: A Phase 1b Study.

Pujol JL, Vansteenkiste J, Paz-Ares Rodríguez L, Gregorc V, Mazieres J, Awad M, Jänne PA, Chisamore M, Hossain AM, Chen Y, Beck JT. Pujol JL, et al. JTO Clin Res Rep. 2021 Sep 25;2(11):100234. doi: 10.1016/j.jtocrr.2021.100234. eCollection 2021 Nov. JTO Clin Res Rep. 2021. PMID: 34746886 Free PMC article.

163

Identification and Management of Pathogenic Variants in BRCA1, BRCA2, and PALB2 in a Tumor-Only Genomic Testing Program.

Bychkovsky BL, Li T, Sotelo J, Tayob N, Mercado J, Gomy I, Chittenden A, Kane S, Stokes S, Hughes ME, Kim JS, Umeton R, Awad MM, Konstantinopoulos PA, Yurgelun MB, Wolpin BM, Taplin ME, Newmark RE, Johnson BE, Lindeman NI, MacConaill LE, Garber JE, Lin NU. Bychkovsky BL, et al. Among authors: awad mm. Clin Cancer Res. 2022 Jun 1;28(11):2349-2360. doi: 10.1158/1078-0432.CCR-21-2861. Clin Cancer Res. 2022. PMID: 35363308 Free PMC article.

164

Genomic Landscapes and Hallmarks of Mutant RAS in Human Cancers.

Scharpf RB, Balan A, Ricciuti B, Fiksel J, Cherry C, Wang C, Lenoue-Newton ML, Rizvi HA, White JR, Baras AS, Anaya J, Landon BV, Majcherska-Agrawal M, Ghanem P, Lee J, Raskin L, Park AS, Tu H, Hsu H, Arbour KC, Awad MM, Riely GJ, Lovly CM, Anagnostou V. Scharpf RB, et al. Among authors: awad mm. Cancer Res. 2022 Nov 2;82(21):4058-4078. doi: 10.1158/0008-5472.CAN-22-1731. Cancer Res. 2022. PMID: 36074020 Free PMC article.

165

STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor Microenvironment.

Koyama S, Akbay EA, Li YY, Aref AR, Skoulidis F, Herter-Sprie GS, Buczkowski KA, Liu Y, Awad MM, Denning WL, Diao L, Wang J, Parra-Cuentas ER, Wistuba II, Soucheray M, Thai T, Asahina H, Kitajima S, Altabef A, Cavanaugh JD, Rhee K, Gao P, Zhang H, Fecci PE, Shimamura T, Hellmann MD, Heymach JV, Hodi FS, Freeman GJ, Barbie DA, Dranoff G, Hammerman PS, Wong KK. Koyama S, et al. Among authors: awad mm. Cancer Res. 2016 Mar 1;76(5):999-1008. doi: 10.1158/0008-5472.CAN-15-1439. Epub 2016 Feb 1. Cancer Res. 2016. PMID: 26833127 Free PMC article.

166

Reply to Cortellini A.

Ricciuti B, Awad MM. Ricciuti B, et al. Among authors: awad mm. JTO Clin Res Rep. 2020 Nov 21;1(4):100095. doi: 10.1016/j.jtocrr.2020.100095. eCollection 2020 Nov. JTO Clin Res Rep. 2020. PMID: 34589967 Free PMC article. No abstract available.

167

Neutrophil-erythrocyte rosettes in autoimmune hemolytic anemia.

Schulman S, Awad MM, Kuter DJ. Schulman S, et al. Among authors: awad mm. Am J Hematol. 2013 Apr;88(4):333-4. doi: 10.1002/ajh.23277. Epub 2012 Aug 7. Am J Hematol. 2013. PMID: 22886729 Free article. No abstract available.

168

Liquid biopsy epigenomic profiling for cancer subtyping.

Baca SC, Seo JH, Davidsohn MP, Fortunato B, Semaan K, Sotudian S, Lakshminarayanan G, Diossy M, Qiu X, El Zarif T, Savignano H, Canniff J, Madueke I, Saliby RM, Zhang Z, Li R, Jiang Y, Taing L, Awad M, Chau CH, DeCaprio JA, Figg WD, Greten TF, Hata AN, Hodi FS, Hughes ME, Ligon KL, Lin N, Ng K, Oser MG, Meador C, Parsons HA, Pomerantz MM, Rajan A, Ritz J, Thakuria M, Tolaney SM, Wen PY, Long H, Berchuck JE, Szallasi Z, Choueiri TK, Freedman ML. Baca SC, et al. Among authors: awad m. Nat Med. 2023 Nov;29(11):2737-2741. doi: 10.1038/s41591-023-02605-z. Epub 2023 Oct 21. Nat Med. 2023. PMID: 37865722 Free PMC article.

169

Author Correction: Liquid biopsy epigenomic profiling for cancer subtyping.

Baca SC, Seo JH, Davidsohn MP, Fortunato B, Semaan K, Sotudian S, Lakshminarayanan G, Diossy M, Qiu X, El Zarif T, Savignano H, Canniff J, Madueke I, Saliby RM, Zhang Z, Li R, Jiang Y, Taing L, Awad M, Chau CH, DeCaprio JA, Figg WD, Greten TF, Hata AN, Hodi FS, Hughes ME, Ligon KL, Lin N, Ng K, Oser MG, Meador C, Parsons HA, Pomerantz MM, Rajan A, Ritz J, Thakuria M, Tolaney SM, Wen PY, Long H, Berchuck JE, Szallasi Z, Choueiri TK, Freedman ML. Baca SC, et al. Among authors: awad m. Nat Med. 2024 Mar;30(3):907. doi: 10.1038/s41591-023-02735-4. Nat Med. 2024. PMID: 38049623 Free PMC article. No abstract available.

170

Activating point mutations in the MET kinase domain represent a unique molecular subset of lung cancer and other malignancies targetable with MET inhibitors.

Pecci F, Nakazawa S, Ricciuti B, Harada G, Lee JK, Alessi JV, Barrichello A, Vaz VR, Lamberti G, Di Federico A, Gandhi MM, Gazgalis D, Feng WW, Jiang J, Baldacci S, Locquet MA, Gottlieb FH, Chen MF, Lee E, Haradon D, Smokovich A, Voligny E, Nguyen T, Goel VK, Zimmerman Z, Atwal S, Wang X, Bahcall M, Heist RS, Iqbal S, Gandhi N, Elliott A, Vanderwalde AM, Ma PC, Halmos B, Liu SV, Che J, Schrock AB, Drilon A, Janne PA, Awad MM. Pecci F, et al. Among authors: awad mm. Cancer Discov. 2024 Apr 3. doi: 10.1158/2159-8290.CD-23-1217. Online ahead of print. Cancer Discov. 2024. PMID: 38564707

171

Osimertinib and Selpercatinib Efficacy, Safety, and Resistance in a Multicenter, Prospectively Treated Cohort of EGFR-Mutant and RET Fusion-Positive Lung Cancers.

Rotow J, Patel JD, Hanley MP, Yu H, Awad M, Goldman JW, Nechushtan H, Scheffler M, Kuo CS, Rajappa S, Harada G, Clifford S, Santucci A, Silva L, Tupper R, Oxnard GR, Kherani J, Drilon A. Rotow J, et al. Clin Cancer Res. 2023 Aug 15;29(16):2979-2987. doi: 10.1158/1078-0432.CCR-22-2189. Clin Cancer Res. 2023. PMID: 36996322 Free PMC article.

172

Loss of p53 and mutational heterogeneity drives immune resistance in an autochthonous mouse lung cancer model with high tumor mutational burden.

Zhu M, Kim J, Deng Q, Ricciuti B, Alessi JV, Eglenen-Polat B, Bender ME, Huang HC, Kowash RR, Cuevas I, Bennett ZT, Gao J, Minna JD, Castrillon DH, Awad MM, Xu L, Akbay EA. Zhu M, et al. Among authors: awad mm. Cancer Cell. 2023 Oct 9;41(10):1731-1748.e8. doi: 10.1016/j.ccell.2023.09.006. Epub 2023 Sep 28. Cancer Cell. 2023. PMID: 37774698

173

DSG2 mutations contribute to arrhythmogenic right ventricular dysplasia/cardiomyopathy.

Awad MM, Dalal D, Cho E, Amat-Alarcon N, James C, Tichnell C, Tucker A, Russell SD, Bluemke DA, Dietz HC, Calkins H, Judge DP. Awad MM, et al. Am J Hum Genet. 2006 Jul;79(1):136-42. doi: 10.1086/504393. Epub 2006 Apr 28. Am J Hum Genet. 2006. PMID: 16773573 Free PMC article.

174

Mechanisms of disease: molecular genetics of arrhythmogenic right ventricular dysplasia/cardiomyopathy.

Awad MM, Calkins H, Judge DP. Awad MM, et al. Nat Clin Pract Cardiovasc Med. 2008 May;5(5):258-67. doi: 10.1038/ncpcardio1182. Epub 2008 Apr 1. Nat Clin Pract Cardiovasc Med. 2008. PMID: 18382419 Free PMC article. Review.

175

Pentobarbital Induced Hypokalemia: A Worrying Sequela.

Awad M, Bonitz J, Pratt A. Awad M, et al. Int J Surg Case Rep. 2020;71:323-326. doi: 10.1016/j.ijscr.2020.05.032. Epub 2020 May 29. Int J Surg Case Rep. 2020. PMID: 32492644 Free PMC article.

176

Recessive arrhythmogenic right ventricular dysplasia due to novel cryptic splice mutation in PKP2.

Awad MM, Dalal D, Tichnell C, James C, Tucker A, Abraham T, Spevak PJ, Calkins H, Judge DP. Awad MM, et al. Hum Mutat. 2006 Nov;27(11):1157. doi: 10.1002/humu.9461. Hum Mutat. 2006. PMID: 17041889 Free PMC article.

177

Tolosa-Hunt Syndrome: A Non-Classical Presentation of a Rare Cause of Unilateral Headache and Painful Ophthalmoplegia.

Douedi S, Awad M, Shenouda D, Mack P, Carson MP. Douedi S, et al. J Clin Med Res. 2020 Apr;12(4):266-268. doi: 10.14740/jocmr4123. Epub 2020 Mar 30. J Clin Med Res. 2020. PMID: 32362975 Free PMC article.

178

Clinical Outcomes of a Large, Prospective Series of Gastric Electrical Stimulation Patients Using a Multidisciplinary Protocol.

Cassidy DJ, Gerull W, Zike VM, Awad MM. Cassidy DJ, et al. Among authors: awad mm. J Am Coll Surg. 2024 Apr 29. doi: 10.1097/XCS.0000000000001105. Online ahead of print. J Am Coll Surg. 2024. PMID: 38682813

179

Potential mitigating impact of a dipeptidyl peptidase-IV inhibitor, vildagliptin, on oxazolone-induced ulcerative colitis: Targeting the role of PI3K/AKT/mTOR and AMPK/Nrf2 signaling pathways.

Awad MM, El-Gohary RM, Ibrahim S, Abdel Ghafar MT, Farghal EE, Aboalsoud A, El-Shaer RAA. Awad MM, et al. Int Immunopharmacol. 2024 Apr 22;133:112110. doi: 10.1016/j.intimp.2024.112110. Online ahead of print. Int Immunopharmacol. 2024. PMID: 38652960

180

Thermal Energy Storage Using Hybrid Nanofluid Phase Change Material (PCM) Based on Waste Sludge Incorp Rated ZnO/α-Fe₂O₃.

Hassan EA, Tony MA, Awad MM. Hassan EA, et al. Among authors: awad mm. Nanomaterials (Basel). 2024 Mar 28;14(7):604. doi: 10.3390/nano14070604. Nanomaterials (Basel). 2024. PMID: 38607138 Free PMC article.

181

Perioperative Risk Factors for Persistent Postsurgical Pain After Inguinal Hernia Repair: Systematic Review and Meta-Analysis.

Alaverdyan H, Maeng J, Park PK, Reddy KN, Gaume MP, Yaeger L, Awad MM, Haroutounian S. Alaverdyan H, et al. Among authors: awad mm. J Pain. 2024 Apr 8:104532. doi: 10.1016/j.jpain.2024.104532. Online ahead of print. J Pain. 2024. PMID: 38599265 Review.

182

Tumor mutational burden for the prediction of PD-(L)1 blockade efficacy in cancer: challenges and opportunities.

Wang X, Lamberti G, Di Federico A, Alessi J, Ferrara R, Sholl ML, Awad MM, N V, Ricciuti B. Wang X, et al. Among authors: awad mm. Ann Oncol. 2024 Mar 25:S0923-7534(24)00084-X. doi: 10.1016/j.annonc.2024.03.007. Online ahead of print. Ann Oncol. 2024. PMID: 38537779 Review.

183

A Capstone Course for Senior Medical Students: from Innovative Elective to Required Core Curriculum.

Wesevich A, De Fer TM, Awad MM, Woodhouse J, Andriole DA, Brunt LM. Wesevich A, et al. Among authors: awad mm. Med Sci Educ. 2023 Dec 27;34(1):171-180. doi: 10.1007/s40670-023-01880-2. eCollection 2024 Feb. Med Sci Educ. 2023. PMID: 38510417

184

Successful Percutaneous Ultrasonic Lithotripsy of Gallstones.

Ostergar A, Alkazemi MH, Hill H, Awad MM, Ushinsky A, Darcy M, Desai AC, Figenshau RS. Ostergar A, et al. Among authors: awad mm. Ochsner J. 2024 Spring;24(1):84-86. doi: 10.31486/toj.23.0071. Ochsner J. 2024. PMID: 38510219 Free PMC article.

185

Mechanisms of piperonyl butoxide cytotoxicity and its enhancement with imidacloprid and metals in Chinese hamster ovary cells.

Awad MM, Chailapakul P, Brown MA, Kato TA. Awad MM, et al. Mutat Res. 2024 Feb 12;828:111853. doi: 10.1016/j.mrfmmm.2024.111853. Online ahead of print. Mutat Res. 2024. PMID: 38401335

186

Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial.

Besse B, Pons-Tostivint E, Park K, Hartl S, Forde PM, Hochmair MJ, Awad MM, Thomas M, Goss G, Wheatley-Price P, Shepherd FA, Florescu M, Cheema P, Chu QSC, Kim SW, Morgensztern D, Johnson ML, Cousin S, Kim DW, Moskovitz MT, Vicente D, Aronson B, Hobson R, Ambrose HJ, Khosla S, Reddy A, Russell DL, Keddar MR, Conway JP, Barrett JC, Dean E, Kumar R, Dressman M, Jewsbury PJ, Iyer S, Barry ST, Cosaert J, Heymach JV. Besse B, et al. Among authors: awad mm. Nat Med. 2024 Mar;30(3):716-729. doi: 10.1038/s41591-024-02808-y. Epub 2024 Feb 13. Nat Med. 2024. PMID: 38351187 Free PMC article. Clinical Trial.

187

Selenium protects against nesfatin-1 modulation of the hypothalamic-pituitary-testicular axis during hypothyroidism in male rats.

El-Shaer RAA, Ibrahim S, Hewady PM, Atef MM, El-Deeb OS, Hafez YM, Amer RS, El-Sharnoby JAE, AbuoHashish NA, Awad MM. El-Shaer RAA, et al. Among authors: awad mm. Physiol Rep. 2024 Jan;12(2):e15923. doi: 10.14814/phy2.15923. Physiol Rep. 2024. PMID: 38268116 Free PMC article.

188

"No-Primer" Resin Cementation of Lithium Disilicate Ceramic: A Microtensile Bond Strength Evaluation.

Awad MM, Alhalabi F, Alanazi AA, Alanazi AA, Alshahrani GA, Fu C, Albaijan RS, Alkattan R, Fawzy AS. Awad MM, et al. Materials (Basel). 2023 Dec 27;17(1):137. doi: 10.3390/ma17010137. Materials (Basel). 2023. PMID: 38203993 Free PMC article.

189

Practical Guide to Ethics in Surgical Education Research.

Awad MM, Kaji AH, Pawlik TM. Awad MM, et al. JAMA Surg. 2024 Jan 3. doi: 10.1001/jamasurg.2023.6705. Online ahead of print. JAMA Surg. 2024. PMID: 38170513

190

National ABSITE Preparation Practices: A Survey of General Surgery Residency Program Directors.

Caldwell KE, Clanahan JM, Klingensmith ME, Wise PE, Awad MM, Dickinson KJ. Caldwell KE, et al. Among authors: awad mm. J Surg Educ. 2024 Jan;81(1):56-63. doi: 10.1016/j.jsurg.2023.10.004. Epub 2023 Nov 30. J Surg Educ. 2024. PMID: 38036385

191

The Advanced Certifying Exam Simulation-Pro assessment instrument: evaluating surgical trainee examsmanship in virtual oral exams.

Smith ER, Clanahan JM, Hess A, Han B, Kushner BS, Pandian TK, Wise PE, Awad MM, Kramer JB. Smith ER, et al. Among authors: awad mm. Global Surg Educ. 2023;2(1):30. doi: 10.1007/s44186-023-00107-7. Epub 2023 Feb 1. Global Surg Educ. 2023. PMID: 38013865 Free PMC article.

192

Stimulator of interferon genes/Interferon regulatory factor 3 (STING-IRF3) and inflammasome-activation mediated pyroptosis biomarkers: a network of integrated pathways in diabetic nephropathy.

El-Deeb OS, Hafez YM, Eltokhy AK, Awad MM, El-Shaer RAA, Abdel Ghafar MT, Atef MM. El-Deeb OS, et al. Among authors: awad mm. J Diabetes Metab Disord. 2023 Aug 9;22(2):1471-1480. doi: 10.1007/s40200-023-01270-w. eCollection 2023 Dec. J Diabetes Metab Disord. 2023. PMID: 37975106

193

Distance travelled: The road remains unclear.

Zarate Rodriguez JG, Awad MM. Zarate Rodriguez JG, et al. Among authors: awad mm. Med Educ. 2024 Feb;58(2):172-173. doi: 10.1111/medu.15268. Epub 2023 Nov 16. Med Educ. 2024. PMID: 37973610 No abstract available.

194

Patient-Reported Health-Related Quality of Life in KEYNOTE-604: Pembrolizumab or Placebo Added to Etoposide and Platinum as First-Line Therapy for Extensive-Stage SCLC.

Kim HR, Awad MM, Navarro A, Gottfried M, Peters S, Csőszi T, Cheema PK, Rodriguez-Abreu D, Wollner M, Yang JC, Mazieres J, Orlandi FJ, Luft A, Gümüş M, Kato T, Kalemkerian GP, Luo Y, Santorelli ML, Pietanza MC, Rudin CM. Kim HR, et al. Among authors: awad mm. JTO Clin Res Rep. 2023 Sep 9;4(11):100572. doi: 10.1016/j.jtocrr.2023.100572. eCollection 2023 Nov. JTO Clin Res Rep. 2023. PMID: 37954964 Free PMC article.

195

Combined Thyroid-Parathyroid Organ Transplantation: Demonstration of Technical Feasibility in a Perfused Cadaver Model.

Brocke TK, Martens GR, Awad MM, Sacks JM, Olson JA Jr. Brocke TK, et al. Among authors: awad mm. J Am Coll Surg. 2024 Feb 1;238(2):e1-e5. doi: 10.1097/XCS.0000000000000899. Epub 2023 Nov 3. J Am Coll Surg. 2024. PMID: 37921360 No abstract available.

196

Novel insights into the augmented effect of curcumin and liraglutide in ameliorating cisplatin-induced nephrotoxicity in rats: Effects on oxidative stress, inflammation, apoptosis and pyroptosis via GSK-3β.

El-Gohary RM, Ghalwash AA, Awad MM, El-Shaer RAA, Ibrahim S, Eltantawy AF, Elmansy A, Okasha AH. El-Gohary RM, et al. Among authors: awad mm. Arch Biochem Biophys. 2023 Nov;749:109801. doi: 10.1016/j.abb.2023.109801. Epub 2023 Oct 24. Arch Biochem Biophys. 2023. PMID: 37884117

197

A derivative-free root-finding algorithm using exponential method and its implementation.

Thota S, Awad MM, Shanmugasundaram P, Rathour L. Thota S, et al. Among authors: awad mm. BMC Res Notes. 2023 Oct 17;16(1):276. doi: 10.1186/s13104-023-06554-1. BMC Res Notes. 2023. PMID: 37848920 Free PMC article.

198

Preference Signaling for General Surgery Residency: How Should Applicants Use Signaling?

Zarate Rodriguez JG, Caldwell KE, Donald CM, Wise PE, Awad MM. Zarate Rodriguez JG, et al. Among authors: awad mm. J Surg Res. 2024 Jan;293:580-586. doi: 10.1016/j.jss.2023.09.023. Epub 2023 Oct 11. J Surg Res. 2024. PMID: 37832310

199

Use of targeted educational resources to improve robotic bariatric surgery training.

Clanahan JM, Awad MM, Dimou FM. Clanahan JM, et al. Among authors: awad mm. Surg Endosc. 2024 Feb;38(2):894-901. doi: 10.1007/s00464-023-10436-9. Epub 2023 Oct 12. Surg Endosc. 2024. PMID: 37823946

200

Green Synthesized Zinc Oxide Nanoparticles Attenuate Acrylamide-Induced Cardiac Injury via Controlling Endoplasmic Reticulum Stress-Associated Apoptosis Through ATF3/CHOP/BCL2 Signaling in Rats.

Alosaimi M, Abd-Elhakim YM, Mohamed AA, Metwally MMM, Khamis T, Alansari WS, Eskandrani AA, Essawi WM, Awad MM, El-Shaer RAA, Ibrahim S, Nassan MA, Metwally AS. Alosaimi M, et al. Among authors: awad mm. Biol Trace Elem Res. 2024 Jun;202(6):2657-2671. doi: 10.1007/s12011-023-03855-1. Epub 2023 Sep 27. Biol Trace Elem Res. 2024. PMID: 37752374

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

328 results

Search Page